{"gene":"TMEM106B","run_date":"2026-06-13T19:06:35","timeline":{"discoveries":[{"year":2012,"finding":"TMEM106B is a type II integral membrane protein with a highly glycosylated luminal domain. Glycosylation (partially required for transport beyond the ER) was established by differential membrane extraction and sequential mutagenesis of N-glycosylation sites. Endogenous and overexpressed TMEM106B localizes to late endosomes and lysosomes. Inhibition of vacuolar H(+)-ATPase significantly increased TMEM106B protein levels.","method":"Differential membrane extraction, sequential N-glycosylation site mutagenesis, subcellular fractionation, immunofluorescence, vacuolar H(+)-ATPase inhibitor treatment","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — multiple orthogonal biochemical methods (mutagenesis, membrane extraction, pharmacological inhibition) in a single focused study establishing membrane topology and localization","pmids":["22511793"],"is_preprint":false},{"year":2012,"finding":"TMEM106B overexpression induces enlargement and poor acidification of endo-lysosomes, impairs mannose-6-phosphate receptor trafficking, and increases intracellular progranulin levels. Endogenous neuronal TMEM106B co-localizes with progranulin in late endo-lysosomes. miR-132 and miR-212 repress TMEM106B expression through shared binding sites in its 3'UTR.","method":"TMEM106B overexpression in neurons, lysosomal pH assay, mannose-6-phosphate receptor trafficking assay, co-localization by immunofluorescence, microRNA binding site validation (luciferase reporter/empirical corroboration), microarray miRNA screen","journal":"The Journal of neuroscience : the official journal of the Society for Neuroscience","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (overexpression phenotype, pH assay, trafficking assay, co-localization, miRNA reporter) converging on consistent findings","pmids":["22895706"],"is_preprint":false},{"year":2012,"finding":"TMEM106B overexpression in cells localizes to late endosome/lysosome compartments, induces morphological changes in lysosomes, delays degradation of endocytic cargoes, and elevates intracellular progranulin levels, likely by attenuating lysosomal degradation of progranulin. TMEM106B protein levels are regulated by lysosomal activity.","method":"Ectopic TMEM106B expression, lysosomal inhibitor treatment, endocytic cargo degradation assay, progranulin level measurement by ELISA/western blot, immunofluorescence co-localization","journal":"Human molecular genetics","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal assays (cargo degradation, progranulin quantification, localization) in a focused mechanistic study, consistent with independent findings in PMID:22895706","pmids":["23136129"],"is_preprint":false},{"year":2013,"finding":"TMEM106B knockdown in primary neurons impairs lysosomal trafficking, blunts dendritic arborization, and increases retrograde lysosomal transport in dendrites. TMEM106B physically interacts with microtubule-associated protein 6 (MAP6). MAP6 overexpression phenocopies TMEM106B knockdown (reduced dendritic branching), and MAP6 knockdown fully rescues the dendritic phenotype of TMEM106B knockdown, consistent with a functional interaction. Expressing dominant-negative RILP to enhance anterograde lysosomal transport also rescues dendrite loss in TMEM106B knockdown neurons.","method":"shRNA knockdown in primary neurons, live-cell lysosome trafficking imaging, Co-immunoprecipitation (TMEM106B–MAP6), dendritic arborization morphometry, dominant-negative RILP expression, epistasis by double knockdown","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal functional epistasis, Co-IP for interaction, live imaging for trafficking, replicated across multiple genetic perturbations in one study","pmids":["24357581"],"is_preprint":false},{"year":2013,"finding":"The TMEM106B coding variant T185S (rs3173615) affects protein stability: the T185 (risk) isoform is present at higher protein levels than S185 (protective) isoform. Cycloheximide chase experiments show S185 degrades faster than T185, potentially due to differences in N-glycosylation at residue N183. Both isoforms have similar effects on progranulin protein levels when overexpressed.","method":"Cycloheximide chase protein stability assay, TMEM106B-specific antibody characterization, ELISA for progranulin, overexpression of T185 and S185 variants","journal":"Journal of neurochemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — cycloheximide chase directly establishes differential degradation rate; single lab, mechanistic follow-up with functional implication","pmids":["23742080"],"is_preprint":false},{"year":2014,"finding":"TMEM106B undergoes regulated intramembrane proteolysis: it is processed by lysosomal proteases to generate an N-terminal fragment containing the transmembrane and intracellular domains, which is then further cleaved into a small, rapidly degraded intracellular domain by the GxGD aspartyl proteases SPPL2a and (to a lesser extent) SPPL2b. The TMEM106B paralog TMEM106A localizes to lysosomes but is not a substrate of SPPL2a or SPPL2b.","method":"Overexpression and inhibitor studies, SPPL2a/SPPL2b knockdown and overexpression, fragment detection by western blot, lysosomal protease inhibitor treatment","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — enzymatic mechanism established by protease identification with mutagenesis-equivalent gain/loss-of-function experiments; negative control (TMEM106A) strengthens specificity","pmids":["24872421"],"is_preprint":false},{"year":2015,"finding":"TMEM106B associates with CHMP2B-positive structures (ESCRT-associated), suggesting involvement in ESCRT pathways. The T185 risk variant is more strongly localized to Rab7-positive late endosomes and more associated with CHMP2B compared to the S185 protective variant. T185 slightly reduces autophagic flux and enhances EGFR accumulation and neurotoxicity caused by mutant CHMP2B(Intron5) compared to S185.","method":"Co-immunoprecipitation (TMEM106B–CHMP2B), immunofluorescence co-localization with Rab5/Rab7, autophagic flux assay, EGFR accumulation assay, neurotoxicity assay","journal":"Molecular brain","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — Co-IP and co-localization establish interaction; autophagic flux and toxicity assays provide functional context; single lab","pmids":["26651479"],"is_preprint":false},{"year":2016,"finding":"Increased TMEM106B expression causes a lysosomal vacuolar phenotype in multiple cell types including neurons, impairs lysosomal acidification and degradative function, and increases cytotoxicity. A lysosomal sorting motif in TMEM106B is required for these effects; abrogation of lysosomal sorting rescues them. TMEM106B-induced lysosomal defects are dependent on C9orf72, as C9orf72 knockdown rescues these defects.","method":"TMEM106B overexpression in multiple cell lines and neurons, lysosomal pH assay, degradative function assay, cytotoxicity assay, lysosomal sorting motif mutagenesis, C9orf72 siRNA knockdown epistasis","journal":"Human molecular genetics","confidence":"High","confidence_rationale":"Tier 2 / Strong — lysosomal sorting motif mutagenesis (Tier 1 element), epistasis with C9orf72 knockdown, multiple cell types, multiple orthogonal readouts","pmids":["27126638"],"is_preprint":false},{"year":2017,"finding":"TMEM106B binds vacuolar-ATPase accessory protein 1 (AP1). TMEM106B deficiency reduces vacuolar-ATPase AP1 and V0 subunits, impairing lysosomal acidification and normalizing elevated lysosomal enzyme levels seen in progranulin-null neurons. In Grn−/− mice, Tmem106b deletion normalizes lysosomal protein levels and rescues FTLD-related behavioral abnormalities and retinal degeneration.","method":"Co-immunoprecipitation (TMEM106B–vacuolar-ATPase AP1), lysosomal pH measurement, transcriptomic and proteomic analysis of Grn−/− and Tmem106b−/− mice, behavioral testing, retinal degeneration assessment","journal":"Neuron","confidence":"High","confidence_rationale":"Tier 2 / Strong — Co-IP identifies binding partner; multiple orthogonal in vivo readouts; mechanistic link between TMEM106B, V-ATPase, and lysosomal acidification established across in vitro and in vivo experiments","pmids":["28728022"],"is_preprint":false},{"year":2018,"finding":"TMEM106B knockdown rescues impaired endolysosomal trafficking and increased dendritic branching caused by mutant CHMP2B in neurons. Mechanistically, mutant CHMP2B stably incorporates onto neuronal endolysosomes and prevents their dendritic trafficking due to failure to recruit VPS4 ATPase (required for CHMP2B release). Antisense oligonucleotides (ASOs) targeting TMEM106B restore endosomal health in this context.","method":"ASO-mediated TMEM106B knockdown, live-cell endolysosome trafficking imaging in neurons, VPS4 recruitment assay, dendritic branching morphometry","journal":"Brain : a journal of neurology","confidence":"High","confidence_rationale":"Tier 2 / Strong — ASO knockdown with mechanistic pathway placement via VPS4/CHMP2B epistasis; live imaging with quantitative phenotype; multiple approaches in one study","pmids":["30496365"],"is_preprint":false},{"year":2018,"finding":"TMEM106B drives lung cancer metastasis by promoting synthesis of enlarged lysosomes laden with elevated active cathepsins. In a TFEB-dependent manner, TMEM106B modulates lysosomal gene expression through the CLEAR pathway. TMEM106B-induced lysosomes undergo calcium-dependent exocytosis, releasing active cathepsins necessary for cancer cell invasion; pharmacological cathepsin inhibition prevents TMEM106B-mediated metastasis in vivo.","method":"Ectopic TMEM106B expression, in vivo metastasis assay (gain-of-function screen), lysosome size/number quantification, cathepsin activity assay, TFEB dependency (siRNA knockdown), calcium-dependent exocytosis assay, pharmacological cathepsin inhibition","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (in vivo screen, TFEB epistasis, cathepsin activity, exocytosis, pharmacological rescue) establishing the TFEB–lysosome–cathepsin secretion axis","pmids":["30013069"],"is_preprint":false},{"year":2018,"finding":"The TMEM106B cytoplasmic domain (N-terminal, cytoplasmic-facing) is intrinsically disordered, with no well-defined tertiary structure, as demonstrated by CD and NMR spectroscopy. Several segments have dynamic/nascent secondary structures and relatively restricted backbone motions (ps-ns timescale), potentially allowing transient interactions with diverse partners.","method":"CD spectroscopy, multi-dimensional NMR spectroscopy ({1H}-15N steady-state NOE, chemical shift analysis)","journal":"PloS one","confidence":"High","confidence_rationale":"Tier 1 / Moderate — direct structural characterization by NMR with CD corroboration; single lab but rigorous biophysical methods","pmids":["30332472"],"is_preprint":false},{"year":2020,"finding":"TMEM106B deficiency in mice leads to enlarged LAMP1-positive vacuoles accumulating at the distal end and within the axon initial segment of motoneurons, increased retrograde axonal transport of lysosomes, lipofuscin accumulation, and autophagosome accumulation, resulting in impaired motor performance. TMEM106B mediates anterograde axonal transport of LAMP1-positive organelles and axonal sorting at the initial segment.","method":"TMEM106B-deficient mouse model, LAMP1 immunofluorescence/confocal imaging, live-cell axonal transport quantification, lipofuscin staining, autophagosome staining, motor behavior testing (facial-nerve-dependent assay)","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 2 / Strong — knockout mouse model with multiple orthogonal readouts (transport imaging, vesicle morphology, behavioral testing) establishing lysosomal transport function at the axon initial segment","pmids":["32160553"],"is_preprint":false},{"year":2020,"finding":"TMEM106B deficiency in mice causes myelination defects with significant reduction of proteolipid protein (PLP) and myelin oligodendrocyte glycoprotein (MOG) levels. TMEM106B localizes to lysosomes in oligodendrocytes, physically interacts with lysosomal protease cathepsin D, and is required to maintain proper cathepsin D levels. TMEM106B deficiency causes lysosome clustering in the perinuclear region and decreased lysosome exocytosis and cell-surface PLP levels. The disease-linked D252N mutation abolishes lysosome enlargement and acidification induced by wild-type TMEM106B overexpression, and instead promotes lysosome perinuclear clustering similar to TMEM106B deficiency.","method":"TMEM106B-deficient mice and Oli-neu cell line, immunofluorescence, western blot (PLP, MOG, cathepsin D), Co-immunoprecipitation (TMEM106B–cathepsin D), lysosome exocytosis assay, cell-surface PLP measurement, D252N mutant overexpression, lysosomal pH assay","journal":"Brain : a journal of neurology","confidence":"High","confidence_rationale":"Tier 2 / Strong — Co-IP establishes binding partner; multiple orthogonal methods in both cell and mouse models; mutant analysis (D252N) provides mechanistic discrimination","pmids":["32572497"],"is_preprint":false},{"year":2021,"finding":"TMEM106B is required for SARS-CoV-2 infection of human cell lines and primary lung cells. TMEM106B overexpression enhances SARS-CoV-2 infection and pseudovirus infection, implicating a role in viral entry. Identified by genome-wide CRISPR functional screen.","method":"Genome-wide CRISPR knockout screen, SARS-CoV-2 infection assay (cell lines and primary lung cells), TMEM106B overexpression/pseudovirus infection assay","journal":"Nature genetics","confidence":"High","confidence_rationale":"Tier 2 / Strong — genome-wide unbiased screen validated by overexpression gain-of-function; multiple cell types tested; consistent with independently published finding","pmids":["33686287"],"is_preprint":false},{"year":2021,"finding":"TMEM106B is predicted, by sequence analysis using PSI-BLAST, HMMER, HHpred, and trRosetta, to contain a late embryogenesis abundant-2 (LEA-2) domain superfamily fold in its luminal domain, which has a conserved lipid-binding groove, suggesting TMEM106B may function as a lipid transfer protein in the lumen of late endocytic organelles.","method":"Computational sequence analysis (PSI-BLAST, HMMER, HHpred, trRosetta structure prediction)","journal":"Proteins","confidence":"Low","confidence_rationale":"Tier 4 / Weak — computational prediction only; no experimental validation of lipid transfer activity in this paper","pmids":["34347309"],"is_preprint":false},{"year":2022,"finding":"Residues 120–254 of the C-terminal luminal domain of TMEM106B form amyloid filaments in human brains with diverse neurodegenerative diseases (tauopathies, amyloid-β amyloidoses, synucleinopathies, TDP-43 proteinopathies) and in neurologically normal aged individuals. Three distinct TMEM106B fibril folds were identified, with no clear relationship between fold and disease type. TMEM106B filaments correlate with a 29-kDa sarkosyl-insoluble fragment and globular cytoplasmic inclusions and form in an age-dependent manner.","method":"Cryo-electron microscopy structure determination, sarkosyl fractionation, C-terminal-specific antibody immunodetection, postmortem human brain analysis","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1 / Strong — cryo-EM structure determination at atomic/near-atomic resolution across 22 subjects and multiple disease types; independently replicated by parallel publication (PMID:35344984, PMID:35247328)","pmids":["35344985"],"is_preprint":false},{"year":2022,"finding":"Amyloid fibrils extracted from FTLD-TDP brains (four FTLD-TDP subclasses) are composed of a 135-residue C-terminal fragment of TMEM106B (not TDP-43 as previously assumed). TDP-43 is present as non-fibrillar aggregates detected by immunogold labelling. TMEM106B fibril structure was solved by cryo-EM.","method":"Cryo-EM structure determination of amyloid fibrils from postmortem FTLD-TDP brain, immunogold labelling for TDP-43, biochemical extraction of fibrils","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1 / Strong — atomic-resolution cryo-EM structure with immunogold verification; consistent with independent parallel publications","pmids":["35344984"],"is_preprint":false},{"year":2022,"finding":"A 135-amino acid C-terminal fragment of TMEM106B forms amyloid fibrils (structure solved at 2.7 Å resolution) common to FTLD-TDP, progressive supranuclear palsy, and dementia with Lewy bodies. The fibril structure is homotypic and consistent across distinct neurodegenerative diseases.","method":"Cryo-electron microscopy (2.7 Å resolution), mass spectrometry, postmortem human brain tissue from multiple diseases","journal":"Cell","confidence":"High","confidence_rationale":"Tier 1 / Strong — near-atomic cryo-EM structure with MS validation across multiple disease types; independent replication of PMID:35344985 and PMID:35344984","pmids":["35247328"],"is_preprint":false},{"year":2022,"finding":"TMEM106B loss causes a block late in autophagy by disrupting autophagosome-to-autolysosome maturation, coinciding with impaired lysosomal acidification, reduced cathepsin activity, and juxtanuclear lysosome clustering. Lysosomal clustering requires Rab7A and is associated with reduced Arl8b-mediated anterograde lysosomal transport. Restoring Arl8b activity in TMEM106B-deficient cells rescues lysosome distribution, autophagy, and DPR protein accumulation.","method":"TMEM106B siRNA knockdown, autophagosome–autolysosome maturation assay (tandem fluorescent LC3 reporter), lysosomal pH measurement, cathepsin activity assay, live-cell lysosome distribution imaging, Rab7A siRNA epistasis, Arl8b overexpression rescue","journal":"Frontiers in cellular neuroscience","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal autophagy/lysosomal assays; genetic epistasis (Rab7A, Arl8b) with rescue; identifies specific mechanistic step (autophagosome maturation via Arl8b)","pmids":["36619668"],"is_preprint":false},{"year":2023,"finding":"TMEM106B serves as an ACE2-independent receptor for SARS-CoV-2 entry into ACE2-negative cells. The luminal domain (LD) of TMEM106B directly engages the receptor-binding motif of SARS-CoV-2 spike (established by X-ray crystallography, cryo-EM, and HDX-MS). Spike substitution E484D enhances TMEM106B binding and TMEM106B-mediated entry. TMEM106B-specific monoclonal antibodies block SARS-CoV-2 infection. TMEM106B also promotes spike-mediated syncytium formation, suggesting a role in viral membrane fusion. TMEM106B acts cooperatively with heparan sulfate.","method":"X-ray crystallography, cryo-EM, hydrogen-deuterium exchange mass spectrometry (HDX-MS), pseudovirus entry assay, monoclonal antibody blocking, syncytium formation assay, ACE2-negative cell infection assay","journal":"Cell","confidence":"High","confidence_rationale":"Tier 1 / Strong — atomic-resolution structure of TMEM106B–spike complex by multiple orthogonal structural methods (X-ray, cryo-EM, HDX-MS) plus functional antibody blocking and entry assays in one rigorous study","pmids":["37421949"],"is_preprint":false},{"year":2023,"finding":"TMEM106B deficiency in mice reduces microglial proliferation and activation and increases microglial apoptosis in response to demyelination. TMEM106B-deficient microglia have increased lysosomal pH and decreased lysosomal enzyme activities. TMEM106B loss causes significant decrease in TREM2 protein levels in microglia. Microglial-specific TMEM106B ablation recapitulates these phenotypes and causes myelination defects.","method":"Conditional (microglial-specific) TMEM106B knockout mice, demyelination model, microglial proliferation/apoptosis assays, lysosomal pH measurement, lysosomal enzyme activity assay, TREM2 western blot, myelination assessment","journal":"Science advances","confidence":"High","confidence_rationale":"Tier 2 / Strong — cell-type-specific conditional knockout with multiple orthogonal mechanistic readouts (TREM2 levels, lysosomal pH, enzyme activity, proliferation) in a focused mechanistic study","pmids":["37146150"],"is_preprint":false},{"year":2024,"finding":"The luminal domain of TMEM106B is cleaved by multiple lysosomal cysteine-type proteases to generate the C-terminal fragment capable of fibril formation. Cysteine-type proteases also perform additional C-terminal trimming of this fragment. Fibrillar TMEM106B was detected in human autopsy material. These cleavage events occur under physiological conditions in cellular models and mouse models.","method":"Cysteine protease inhibitors, custom antibody against luminal domain, western blot in knockout and wild-type cellular/mouse models, immunodetection of fibrils in human autopsy material","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 1 / Moderate — protease identity established by pharmacological inhibition in well-controlled KO vs. WT models; fibril detection in human tissue; commercially available antibody validated in KO controls","pmids":["39709600"],"is_preprint":false},{"year":2024,"finding":"TMEM106B physically interacts with galactosylceramidase (co-immunoprecipitation). TMEM106B deficiency significantly increases galactosylceramidase activity and decreases levels of galactosylceramide and sulfatide (major myelin lipids) in mouse brain, establishing that TMEM106B regulates myelin lipid metabolism through modulation of galactosylceramidase.","method":"Lipidomic analysis of TMEM106B-deficient mouse brain, co-immunoprecipitation (TMEM106B–galactosylceramidase), galactosylceramidase activity assay","journal":"Communications biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — Co-IP establishes physical interaction; lipidomics and enzyme activity assay provide orthogonal functional evidence; in vivo mouse model","pmids":["39237682"],"is_preprint":false},{"year":2024,"finding":"TMEM106B deletion in a tauopathy mouse model (P301S tau) accelerates cognitive decline, hind limb paralysis, tau pathology, and neurodegeneration. In contrast, the T185S (T186S in mouse) coding variant protects against tau-associated cognitive decline, synaptic impairment, neurodegeneration, and paralysis without affecting tau pathology itself, demonstrating the coding variant is functionally relevant and acts downstream of tau aggregation.","method":"TMEM106B knockout and T186S knock-in mice crossed with P301S tau transgenic model, behavioral testing (cognitive, motor), tau pathology quantification, synaptic marker analysis, neurodegeneration assessment, transcriptomic correlation with human AD","journal":"Acta neuropathologica","confidence":"High","confidence_rationale":"Tier 2 / Strong — parallel KO and knock-in alleles in tauopathy model; multiple orthogonal phenotypic readouts; genetic dissection of variant-specific effects in a single study","pmids":["38526616"],"is_preprint":false},{"year":2024,"finding":"Loss of TMEM106B enhances accumulation of pathological tau (especially in neuronal soma in hippocampus) and causes severe neuronal loss, cytoskeletal abnormalities, increased autophagy-lysosome dysfunction, and glial activation in PS19 tau transgenic mice, indicating TMEM106B is required to limit tau pathology progression.","method":"Tmem106b−/− × PS19 tau transgenic cross, immunofluorescence for phospho-tau, neuronal count, cytoskeletal markers, autophagy-lysosome markers, glial activation markers","journal":"Acta neuropathologica","confidence":"High","confidence_rationale":"Tier 2 / Strong — double transgenic mouse model with multiple orthogonal readouts; independently replicates finding of PMID:38526616 in a distinct tau model","pmids":["38526799"],"is_preprint":false},{"year":2021,"finding":"Partial knockdown of TMEM106B (to levels expected in rs1990622 C-allele carriers) in an inducible TDP-43 mislocalization cell system leads to more TDP-43 cytoplasmic aggregates that are more insoluble, supporting a causal role for TMEM106B in modifying TDP-43 proteinopathy.","method":"Inducible TDP-43 mislocalization cell system, TMEM106B siRNA partial knockdown, TDP-43 aggregate quantification, solubility fractionation (filter trap assay)","journal":"Acta neuropathologica","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — clean cell-based mechanistic experiment with defined phenotype; single lab, single experimental system","pmids":["34152475"],"is_preprint":false},{"year":2025,"finding":"Transgenic mice overexpressing human TMEM106B (4–8-fold increase) develop lysosomal dysfunction, age-related downregulation of genes associated with neuronal plasticity and memory, altered synaptic signaling, anxiety-like phenotype, and mild hippocampal neuronal loss, establishing that elevated TMEM106B levels are sufficient to impair lysosomal and neuronal health.","method":"Cre-inducible transgenic mouse model, transmission electron microscopy, immunostaining, behavioral testing, electrophysiology, bulk RNA sequencing","journal":"Molecular neurodegeneration","confidence":"High","confidence_rationale":"Tier 2 / Strong — first transgenic overexpression mouse model; multiple orthogonal readouts (EM, electrophysiology, behavior, transcriptomics); establishes gain-of-function lysosomal and neuronal consequences","pmids":["40269985"],"is_preprint":false}],"current_model":"TMEM106B is a type II integral membrane protein resident in late endosomes and lysosomes, where it regulates lysosomal morphology, acidification (through interaction with vacuolar-ATPase subunits), lysosomal enzyme levels, anterograde axonal and dendritic lysosomal transport (via interaction with MAP6), and autophagosome-to-autolysosome maturation (via Arl8b); its luminal domain is cleaved by lysosomal cysteine proteases, and the resulting C-terminal fragment (residues 120–254) forms age-dependent amyloid fibrils with three distinct cryo-EM-resolved folds found across diverse neurodegenerative diseases; TMEM106B also interacts with galactosylceramidase to regulate myelin lipid metabolism, promotes microglial lysosomal function and TREM2 levels, and acts as an ACE2-independent entry receptor for SARS-CoV-2 through direct spike RBM engagement of its luminal domain."},"narrative":{"mechanistic_narrative":"TMEM106B is a type II integral membrane protein resident in late endosomes and lysosomes that governs lysosomal morphology, acidification, positioning, and degradative capacity, thereby acting as a central regulator of endolysosomal and autophagic homeostasis in neurons, glia, and other cell types [PMID:22511793, PMID:22895706, PMID:27126638]. Its highly glycosylated luminal domain faces the lysosomal lumen, while its intrinsically disordered cytoplasmic N-terminus enables transient interactions; protein levels are tuned by lysosomal activity and by the miR-132/miR-212 cluster [PMID:22511793, PMID:30332472, PMID:22895706]. TMEM106B promotes lysosomal acidification by binding the vacuolar-ATPase accessory protein AP1 and supporting V-ATPase subunit levels, and its loss reduces acidification and normalizes the elevated lysosomal enzyme and protein levels seen in progranulin-null neurons—Tmem106b deletion rescues FTLD-related phenotypes in Grn-/- mice [PMID:28728022]. It controls anterograde lysosomal transport along axons and dendrites through interaction with MAP6 and through Arl8b-dependent positioning, such that its loss causes retrograde transport bias, perinuclear/juxtanuclear lysosome clustering, and a block in autophagosome-to-autolysosome maturation [PMID:24357581, PMID:32160553, PMID:36619668]. TMEM106B regulates lysosomal protease and lipid metabolism via physical interactions with cathepsin D and galactosylceramidase, controlling myelin lipid (galactosylceramide/sulfatide) levels and oligodendrocyte function, and it sustains microglial lysosomal function and TREM2 levels [PMID:32572497, PMID:39237682, PMID:37146150]. The luminal domain is cleaved by lysosomal cysteine proteases to generate a C-terminal fragment (residues ~120–254) that forms age-dependent amyloid fibrils with three distinct cryo-EM folds across diverse neurodegenerative diseases—these fibrils, rather than TDP-43, constitute the filaments previously attributed to FTLD-TDP brains [PMID:39709600, PMID:35344985, PMID:35344984, PMID:35247328]. Both gain and loss of TMEM106B are pathogenic: overexpression causes lysosomal vacuolation, impaired acidification, cytotoxicity, and neuronal dysfunction, while loss accelerates tau and TDP-43 proteinopathy, and the protective T185S coding variant acts downstream of tau aggregation to preserve neuronal health [PMID:27126638, PMID:40269985, PMID:38526616, PMID:34152475]. Independently of its lysosomal role, TMEM106B serves as an ACE2-independent entry receptor for SARS-CoV-2, with its luminal domain directly engaging the spike receptor-binding motif [PMID:37421949, PMID:33686287].","teleology":[{"year":2012,"claim":"Establishing that TMEM106B is a glycosylated type II membrane protein resident in late endosomes/lysosomes whose levels are set by lysosomal activity defined the compartment in which all subsequent function would be interpreted.","evidence":"Differential membrane extraction, N-glycosylation mutagenesis, fractionation, and V-ATPase inhibitor treatment","pmids":["22511793"],"confidence":"High","gaps":["Topology established but luminal-domain function not defined","No partners identified at this stage"]},{"year":2012,"claim":"Demonstrating that TMEM106B overexpression enlarges and de-acidifies lysosomes, impairs M6PR trafficking and cargo degradation, and raises progranulin levels linked the protein mechanistically to lysosomal degradative function and the FTLD progranulin axis.","evidence":"Overexpression in neurons/cells, lysosomal pH and trafficking assays, progranulin ELISA, miRNA reporter validation","pmids":["22895706","23136129"],"confidence":"High","gaps":["Gain-of-function phenotype; physiological loss-of-function role unresolved","Direct molecular cause of acidification defect not identified"]},{"year":2013,"claim":"Identifying the MAP6 interaction and reciprocal epistasis established that TMEM106B drives anterograde lysosomal transport required for dendritic arborization, moving the protein from a static lysosomal marker to a transport regulator.","evidence":"shRNA knockdown in primary neurons, live lysosome imaging, Co-IP, dominant-negative RILP rescue, double knockdown","pmids":["24357581"],"confidence":"High","gaps":["Direct biochemical bridge between luminal TMEM106B and cytoplasmic motor machinery not resolved","Whether MAP6 binding is direct vs. complex-mediated unclear"]},{"year":2013,"claim":"Showing that the risk T185 isoform is more stable than the protective S185 isoform provided a candidate molecular basis for the disease-associated coding variant.","evidence":"Cycloheximide chase stability assay, isoform-specific overexpression, progranulin ELISA","pmids":["23742080"],"confidence":"Medium","gaps":["Stability difference correlated with but not proven to cause disease risk","Glycosylation mechanism at N183 inferred, not directly demonstrated"]},{"year":2014,"claim":"Defining regulated intramembrane proteolysis by lysosomal proteases and SPPL2a/SPPL2b established a processing pathway for TMEM106B and distinguished it from the non-substrate paralog TMEM106A.","evidence":"SPPL2a/SPPL2b knockdown/overexpression, protease inhibitors, fragment western blots","pmids":["24872421"],"confidence":"High","gaps":["Functional consequence of the released intracellular fragment unknown","Relationship of this processing to fibril-forming luminal fragment not yet connected"]},{"year":2016,"claim":"Mapping the lysosomal sorting motif requirement and C9orf72 dependence of the overexpression phenotype tied TMEM106B-driven lysosomal toxicity to specific trafficking determinants and a known FTD/ALS gene.","evidence":"Overexpression in multiple cell types, sorting motif mutagenesis, lysosomal pH/degradation/cytotoxicity assays, C9orf72 siRNA epistasis","pmids":["27126638"],"confidence":"High","gaps":["Molecular nature of C9orf72 dependence not defined","ESCRT/CHMP2B association reported separately but mechanistically incomplete"]},{"year":2017,"claim":"Identifying the V-ATPase accessory protein AP1 as a binding partner and showing Tmem106b deletion rescues Grn-/- lysosomal and behavioral phenotypes established the molecular basis of TMEM106B-dependent acidification and its in vivo modifier role in FTLD.","evidence":"Co-IP, lysosomal pH measurement, transcriptomics/proteomics in Grn-/- × Tmem106b-/- mice, behavioral and retinal assessment","pmids":["28728022"],"confidence":"High","gaps":["Direct stoichiometry/assembly with V-ATPase not resolved","Whether AP1 binding is luminal or cytoplasmic not specified"]},{"year":2018,"claim":"A series of studies extended TMEM106B function to autophagic flux (CHMP2B/ESCRT context), VPS4-dependent endolysosome trafficking, cancer metastasis via TFEB-driven lysosomal cathepsin secretion, and defined its cytoplasmic domain as intrinsically disordered, broadening its mechanistic reach.","evidence":"Co-IP, CHMP2B/VPS4 epistasis, in vivo metastasis and cathepsin/exocytosis assays with TFEB knockdown, CD/NMR spectroscopy","pmids":["26651479","30496365","30013069","30332472"],"confidence":"High","gaps":["How disordered cytoplasmic domain selects diverse partners undefined","Direct vs. indirect role in TFEB/CLEAR regulation unresolved"]},{"year":2020,"claim":"Knockout mice revealed that TMEM106B mediates anterograde axonal lysosome transport and axon-initial-segment sorting and physically interacts with cathepsin D to regulate myelination, linking lysosomal positioning and protease control to neuronal and oligodendrocyte integrity.","evidence":"TMEM106B-deficient mice and Oli-neu cells, axonal transport imaging, lipofuscin/autophagosome staining, motor testing, Co-IP with cathepsin D, D252N mutant analysis","pmids":["32160553","32572497"],"confidence":"High","gaps":["Mechanism by which D252N inverts the gain-of-function phenotype not fully resolved","Direct vs. regulatory role on cathepsin D activity unclear"]},{"year":2021,"claim":"A genome-wide CRISPR screen identified TMEM106B as required for SARS-CoV-2 infection and entry, revealing a function entirely distinct from its lysosomal role.","evidence":"Genome-wide CRISPR knockout screen, infection of cell lines/primary lung cells, overexpression/pseudovirus assays","pmids":["33686287"],"confidence":"High","gaps":["Mechanism of entry (receptor vs. cofactor) not yet defined in this study","Relationship to lysosomal residence unclear"]},{"year":2021,"claim":"Computational analysis predicting a LEA-2 lipid-binding fold in the luminal domain offered a structural hypothesis for a lipid-handling function.","evidence":"PSI-BLAST, HMMER, HHpred, trRosetta structure prediction","pmids":["34347309"],"confidence":"Low","gaps":["Computational prediction only; no experimental validation of lipid transfer activity","Predicted fold not yet reconciled with experimental luminal structures"]},{"year":2021,"claim":"Partial knockdown mimicking risk-allele expression increased and insolubilized TDP-43 cytoplasmic aggregates, providing causal support for TMEM106B as a modifier of TDP-43 proteinopathy.","evidence":"Inducible TDP-43 mislocalization cell system, siRNA partial knockdown, aggregate quantification, filter-trap solubility assay","pmids":["34152475"],"confidence":"Medium","gaps":["Single cell-based system; in vivo confirmation absent here","Mechanism connecting lysosomal function to TDP-43 aggregation not defined"]},{"year":2022,"claim":"Cryo-EM determination of TMEM106B amyloid fibrils from human brain established that the C-terminal luminal fragment, not TDP-43, forms the filaments in FTLD-TDP and across diverse neurodegenerative diseases and aged brains, overturning a prior assumption and defining an age-dependent amyloid.","evidence":"Cryo-EM structure determination across multiple diseases/subjects, sarkosyl fractionation, immunogold for TDP-43, mass spectrometry","pmids":["35344985","35344984","35247328"],"confidence":"High","gaps":["Whether fibrils are pathogenic, protective, or bystander not resolved","No clear fold–disease relationship established","Trigger of age-dependent fibril formation unknown"]},{"year":2022,"claim":"Demonstrating an Arl8b- and Rab7A-dependent block in autophagosome-to-autolysosome maturation upon TMEM106B loss placed the protein at a defined step of autophagy and lysosomal positioning, with Arl8b restoration rescuing the defect.","evidence":"siRNA knockdown, tandem LC3 maturation reporter, lysosomal pH and cathepsin assays, Rab7A epistasis, Arl8b overexpression rescue","pmids":["36619668"],"confidence":"High","gaps":["Direct interaction with Arl8b vs. indirect regulation not established","Link between maturation block and DPR accumulation mechanism incomplete"]},{"year":2023,"claim":"Structural determination of the TMEM106B luminal domain–spike complex established TMEM106B as a bona fide ACE2-independent SARS-CoV-2 entry receptor engaging the spike receptor-binding motif, with neutralizing antibody and syncytium evidence.","evidence":"X-ray crystallography, cryo-EM, HDX-MS, pseudovirus entry, monoclonal antibody blocking, syncytium assay","pmids":["37421949"],"confidence":"High","gaps":["In vivo relevance to COVID-19 pathology not established here","Interplay with ACE2-positive cells unclear"]},{"year":2023,"claim":"Microglial-specific knockout showed TMEM106B sustains microglial lysosomal function and TREM2 levels and supports proliferation/survival during demyelination, extending its role into neuroimmune lysosomal biology.","evidence":"Conditional microglial knockout mice, demyelination model, proliferation/apoptosis assays, lysosomal pH and enzyme activity, TREM2 western blot","pmids":["37146150"],"confidence":"High","gaps":["Mechanism linking TMEM106B to TREM2 stability not defined","Direct vs. lysosome-mediated effect on TREM2 unclear"]},{"year":2024,"claim":"Identifying lysosomal cysteine proteases as the enzymes that cleave and trim the luminal domain to the fibril-forming fragment connected physiological proteolysis to amyloid generation.","evidence":"Cysteine protease inhibitors, luminal-domain antibody, western blots in KO vs WT cells/mice, fibril detection in human autopsy tissue","pmids":["39709600"],"confidence":"High","gaps":["Specific protease identity at species level not narrowed","Why cleavage products become amyloidogenic with age unresolved"]},{"year":2024,"claim":"The galactosylceramidase interaction and lipidomic consequences of TMEM106B loss established that TMEM106B regulates myelin lipid metabolism by modulating a lysosomal lipid-degrading enzyme.","evidence":"Co-IP, galactosylceramidase activity assay, brain lipidomics in TMEM106B-deficient mice","pmids":["39237682"],"confidence":"High","gaps":["Whether TMEM106B inhibits or scaffolds galactosylceramidase mechanistically unclear","Connection to predicted luminal lipid-binding fold not tested"]},{"year":2024,"claim":"Crossing TMEM106B knockout and T185S knock-in alleles into tauopathy models demonstrated that loss accelerates tau pathology and neurodegeneration while the protective coding variant preserves neuronal health downstream of tau aggregation, proving the variant is functionally relevant in vivo.","evidence":"Tmem106b KO and T186S knock-in × P301S/PS19 tau mice, behavioral/motor testing, tau pathology and synaptic/neurodegeneration readouts","pmids":["38526616","38526799"],"confidence":"High","gaps":["Molecular pathway by which TMEM106B limits tau-driven degeneration not fully defined","How T185S acts downstream of tau aggregation mechanistically unclear"]},{"year":2025,"claim":"A transgenic overexpression mouse model established that elevated TMEM106B levels alone are sufficient to cause lysosomal dysfunction, synaptic/transcriptomic decline, and neuronal loss, confirming pathogenic gain of function in vivo.","evidence":"Cre-inducible transgenic mice, electron microscopy, electrophysiology, behavior, bulk RNA-seq","pmids":["40269985"],"confidence":"High","gaps":["Whether overexpression toxicity proceeds via fibril formation untested here","Relationship of gain-of-function to loss-of-function phenotypes unresolved"]},{"year":null,"claim":"Whether the age-dependent amyloid fibrils are pathogenic, protective, or incidental, and how a single protein reconciles opposing gain- and loss-of-function disease mechanisms, remains the central unresolved question.","evidence":"","pmids":[],"confidence":"High","gaps":["No causal demonstration that fibrils drive neurodegeneration","No unified model linking lysosomal dysfunction, fibril formation, and the protective coding variant","Physiological function of the predicted luminal lipid-binding fold experimentally untested"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0060090","term_label":"molecular adaptor activity","supporting_discovery_ids":[3,8,23,13]},{"term_id":"GO:0001618","term_label":"virus receptor activity","supporting_discovery_ids":[20,14]},{"term_id":"GO:0005198","term_label":"structural molecule activity","supporting_discovery_ids":[16,17,18]}],"localization":[{"term_id":"GO:0005764","term_label":"lysosome","supporting_discovery_ids":[0,1,2,7,13]},{"term_id":"GO:0005768","term_label":"endosome","supporting_discovery_ids":[0,6,9]},{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[20]}],"pathway":[{"term_id":"R-HSA-9612973","term_label":"Autophagy","supporting_discovery_ids":[19,6]},{"term_id":"R-HSA-5653656","term_label":"Vesicle-mediated transport","supporting_discovery_ids":[3,12,19]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[16,17,24,25,26]},{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[23,13]}],"complexes":[],"partners":["MAP6","ATP6AP1","CHMP2B","CTSD","GALC","ARL8B","RAB7A"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q9NUM4","full_name":"Transmembrane protein 106B","aliases":[],"length_aa":274,"mass_kda":31.1,"function":"In neurons, involved in the transport of late endosomes/lysosomes (PubMed:25066864). May be involved in dendrite morphogenesis and maintenance by regulating lysosomal trafficking (PubMed:25066864). May act as a molecular brake for retrograde transport of late endosomes/lysosomes, possibly via its interaction with MAP6 (By similarity). In motoneurons, may mediate the axonal transport of lysosomes and axonal sorting at the initial segment (By similarity). It remains unclear whether TMEM106B affects the transport of moving lysosomes in the anterograde or retrograde direction in neurites and whether it is important in the sorting of lysosomes in axons or in dendrites (By similarity). In neurons, may also play a role in the regulation of lysosomal size and responsiveness to stress (PubMed:25066864). Required for proper lysosomal acidification (By similarity) (Microbial infection) Plays a role in human coronavirus SARS-CoV-2 infection, but not in common cold coronaviruses HCoV-229E and HCoV-OC43 infections. Involved in ACE2-independent SARS-CoV-2 cell entry. Required for post-endocytic stage of virus entry, facilitates spike-mediated membrane fusion. Virus attachment and endocytosis can also be mediated by other cell surface receptors","subcellular_location":"Late endosome membrane; Lysosome membrane; Cell membrane","url":"https://www.uniprot.org/uniprotkb/Q9NUM4/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/TMEM106B","classification":"Not Classified","n_dependent_lines":4,"n_total_lines":1208,"dependency_fraction":0.0033112582781456954},"opencell":{"profiled":true,"resolved_as":"","ensg_id":"ENSG00000106460","cell_line_id":"CID002001","localizations":[{"compartment":"vesicles","grade":3},{"compartment":"membrane","grade":1}],"interactors":[{"gene":"AGTRAP","stoichiometry":0.2},{"gene":"LAMTOR1","stoichiometry":0.2},{"gene":"TMEM55B","stoichiometry":0.2},{"gene":"STK11IP","stoichiometry":0.2},{"gene":"SLC35F6","stoichiometry":0.2},{"gene":"STX12","stoichiometry":0.2},{"gene":"TMEM192","stoichiometry":0.2},{"gene":"TMEM106C","stoichiometry":0.2},{"gene":"GOLPH3","stoichiometry":0.2},{"gene":"STX7","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/target/CID002001","total_profiled":1310},"omim":[{"mim_id":"617964","title":"LEUKODYSTROPHY, HYPOMYELINATING, 16; HLD16","url":"https://www.omim.org/entry/617964"},{"mim_id":"613487","title":"MICRO RNA 212; MIR212","url":"https://www.omim.org/entry/613487"},{"mim_id":"613413","title":"TRANSMEMBRANE PROTEIN 106B; TMEM106B","url":"https://www.omim.org/entry/613413"},{"mim_id":"610016","title":"MICRO RNA 132; MIR132","url":"https://www.omim.org/entry/610016"},{"mim_id":"609512","title":"CHARGED MULTIVESICULAR BODY PROTEIN 2B; CHMP2B","url":"https://www.omim.org/entry/609512"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Endosomes","reliability":"Supported"},{"location":"Lysosomes","reliability":"Supported"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/TMEM106B"},"hgnc":{"alias_symbol":["MGC33727","FLJ11273"],"prev_symbol":[]},"alphafold":{"accession":"Q9NUM4","domains":[{"cath_id":"2.60.40.10","chopping":"120-259","consensus_level":"high","plddt":94.0755,"start":120,"end":259}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9NUM4","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q9NUM4-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q9NUM4-F1-predicted_aligned_error_v6.png","plddt_mean":75.88},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=TMEM106B","jax_strain_url":"https://www.jax.org/strain/search?query=TMEM106B"},"sequence":{"accession":"Q9NUM4","fasta_url":"https://rest.uniprot.org/uniprotkb/Q9NUM4.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q9NUM4/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9NUM4"}},"corpus_meta":[{"pmid":"21178100","id":"PMC_21178100","title":"TMEM106B regulates progranulin levels and the penetrance of FTLD in GRN mutation carriers.","date":"2010","source":"Neurology","url":"https://pubmed.ncbi.nlm.nih.gov/21178100","citation_count":219,"is_preprint":false},{"pmid":"22895706","id":"PMC_22895706","title":"TMEM106B, the risk gene for frontotemporal dementia, is regulated by the microRNA-132/212 cluster and affects progranulin pathways.","date":"2012","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/22895706","citation_count":203,"is_preprint":false},{"pmid":"33686287","id":"PMC_33686287","title":"Genome-wide CRISPR screening identifies TMEM106B as a proviral host factor for SARS-CoV-2.","date":"2021","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/33686287","citation_count":191,"is_preprint":false},{"pmid":"23136129","id":"PMC_23136129","title":"The frontotemporal lobar degeneration risk factor, TMEM106B, regulates lysosomal morphology and function.","date":"2012","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/23136129","citation_count":172,"is_preprint":false},{"pmid":"35344985","id":"PMC_35344985","title":"Age-dependent formation of TMEM106B amyloid filaments in human brains.","date":"2022","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/35344985","citation_count":166,"is_preprint":false},{"pmid":"21220649","id":"PMC_21220649","title":"Association of TMEM106B gene polymorphism with age at onset in granulin mutation carriers and plasma granulin protein levels.","date":"2011","source":"Archives of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/21220649","citation_count":150,"is_preprint":false},{"pmid":"24357581","id":"PMC_24357581","title":"The FTLD risk factor TMEM106B and MAP6 control dendritic trafficking of lysosomes.","date":"2013","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/24357581","citation_count":147,"is_preprint":false},{"pmid":"28728022","id":"PMC_28728022","title":"Loss of TMEM106B Ameliorates Lysosomal and Frontotemporal Dementia-Related Phenotypes in Progranulin-Deficient Mice.","date":"2017","source":"Neuron","url":"https://pubmed.ncbi.nlm.nih.gov/28728022","citation_count":145,"is_preprint":false},{"pmid":"35344984","id":"PMC_35344984","title":"Amyloid fibrils in FTLD-TDP are composed of TMEM106B and not TDP-43.","date":"2022","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/35344984","citation_count":140,"is_preprint":false},{"pmid":"24385136","id":"PMC_24385136","title":"TMEM106B protects C9ORF72 expansion carriers against frontotemporal dementia.","date":"2014","source":"Acta neuropathologica","url":"https://pubmed.ncbi.nlm.nih.gov/24385136","citation_count":137,"is_preprint":false},{"pmid":"22511793","id":"PMC_22511793","title":"Membrane orientation and subcellular localization of transmembrane protein 106B (TMEM106B), a major risk factor for frontotemporal lobar degeneration.","date":"2012","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/22511793","citation_count":136,"is_preprint":false},{"pmid":"35247328","id":"PMC_35247328","title":"Homotypic fibrillization of TMEM106B across diverse neurodegenerative diseases.","date":"2022","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/35247328","citation_count":130,"is_preprint":false},{"pmid":"24442578","id":"PMC_24442578","title":"TMEM106B is a genetic modifier of frontotemporal lobar degeneration with C9orf72 hexanucleotide repeat expansions.","date":"2014","source":"Acta neuropathologica","url":"https://pubmed.ncbi.nlm.nih.gov/24442578","citation_count":125,"is_preprint":false},{"pmid":"37421949","id":"PMC_37421949","title":"TMEM106B is a receptor mediating ACE2-independent SARS-CoV-2 cell entry.","date":"2023","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/37421949","citation_count":116,"is_preprint":false},{"pmid":"30013069","id":"PMC_30013069","title":"TMEM106B drives lung cancer metastasis by inducing TFEB-dependent lysosome synthesis and secretion of cathepsins.","date":"2018","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/30013069","citation_count":116,"is_preprint":false},{"pmid":"21354975","id":"PMC_21354975","title":"TMEM106B is associated with frontotemporal lobar degeneration in a clinically diagnosed patient cohort.","date":"2011","source":"Brain : a journal of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/21354975","citation_count":112,"is_preprint":false},{"pmid":"28330615","id":"PMC_28330615","title":"Differential Aging Analysis in Human Cerebral Cortex Identifies Variants in TMEM106B and GRN that Regulate Aging Phenotypes.","date":"2017","source":"Cell systems","url":"https://pubmed.ncbi.nlm.nih.gov/28330615","citation_count":109,"is_preprint":false},{"pmid":"21104415","id":"PMC_21104415","title":"Risk genotypes at TMEM106B are associated with cognitive impairment in amyotrophic lateral sclerosis.","date":"2010","source":"Acta neuropathologica","url":"https://pubmed.ncbi.nlm.nih.gov/21104415","citation_count":107,"is_preprint":false},{"pmid":"23742080","id":"PMC_23742080","title":"TMEM106B p.T185S regulates TMEM106B protein levels: implications for frontotemporal dementia.","date":"2013","source":"Journal of neurochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/23742080","citation_count":102,"is_preprint":false},{"pmid":"27543298","id":"PMC_27543298","title":"What we know about TMEM106B in neurodegeneration.","date":"2016","source":"Acta neuropathologica","url":"https://pubmed.ncbi.nlm.nih.gov/27543298","citation_count":94,"is_preprint":false},{"pmid":"33386471","id":"PMC_33386471","title":"Physiological and pathological functions of TMEM106B: a gene associated with brain aging and multiple brain disorders.","date":"2021","source":"Acta neuropathologica","url":"https://pubmed.ncbi.nlm.nih.gov/33386471","citation_count":88,"is_preprint":false},{"pmid":"32852886","id":"PMC_32852886","title":"Loss of TMEM106B and PGRN leads to severe lysosomal abnormalities and neurodegeneration in mice.","date":"2020","source":"EMBO reports","url":"https://pubmed.ncbi.nlm.nih.gov/32852886","citation_count":86,"is_preprint":false},{"pmid":"25653292","id":"PMC_25653292","title":"The TMEM106B locus and TDP-43 pathology in older persons without FTLD.","date":"2015","source":"Neurology","url":"https://pubmed.ncbi.nlm.nih.gov/25653292","citation_count":81,"is_preprint":false},{"pmid":"33461566","id":"PMC_33461566","title":"rs1990622 variant associates with Alzheimer's disease and regulates TMEM106B expression in human brain tissues.","date":"2021","source":"BMC medicine","url":"https://pubmed.ncbi.nlm.nih.gov/33461566","citation_count":77,"is_preprint":false},{"pmid":"29186371","id":"PMC_29186371","title":"A recurrent de novo mutation in TMEM106B causes hypomyelinating leukodystrophy.","date":"2017","source":"Brain : a journal of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/29186371","citation_count":74,"is_preprint":false},{"pmid":"31456032","id":"PMC_31456032","title":"The TMEM106B FTLD-protective variant, rs1990621, is also associated with increased neuronal proportion.","date":"2019","source":"Acta neuropathologica","url":"https://pubmed.ncbi.nlm.nih.gov/31456032","citation_count":67,"is_preprint":false},{"pmid":"32160553","id":"PMC_32160553","title":"The FTLD Risk Factor TMEM106B Regulates the Transport of Lysosomes at the Axon Initial Segment of Motoneurons.","date":"2020","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/32160553","citation_count":66,"is_preprint":false},{"pmid":"25470345","id":"PMC_25470345","title":"Reassessment of risk genotypes (GRN, TMEM106B, and ABCC9 variants) associated with hippocampal sclerosis of aging pathology.","date":"2015","source":"Journal of neuropathology and experimental neurology","url":"https://pubmed.ncbi.nlm.nih.gov/25470345","citation_count":66,"is_preprint":false},{"pmid":"27126638","id":"PMC_27126638","title":"Increased expression of the frontotemporal dementia risk factor TMEM106B causes C9orf72-dependent alterations in lysosomes.","date":"2016","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/27126638","citation_count":61,"is_preprint":false},{"pmid":"36527486","id":"PMC_36527486","title":"Accumulation of TMEM106B C-terminal fragments in neurodegenerative disease and aging.","date":"2022","source":"Acta neuropathologica","url":"https://pubmed.ncbi.nlm.nih.gov/36527486","citation_count":59,"is_preprint":false},{"pmid":"32929860","id":"PMC_32929860","title":"Loss of TMEM106B potentiates lysosomal and FTLD-like pathology in progranulin-deficient mice.","date":"2020","source":"EMBO reports","url":"https://pubmed.ncbi.nlm.nih.gov/32929860","citation_count":55,"is_preprint":false},{"pmid":"32504082","id":"PMC_32504082","title":"Loss of TMEM106B leads to myelination deficits: implications for frontotemporal dementia treatment strategies.","date":"2020","source":"Brain : a journal of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/32504082","citation_count":52,"is_preprint":false},{"pmid":"28460069","id":"PMC_28460069","title":"Cognitive reserve and TMEM106B genotype modulate brain damage in presymptomatic frontotemporal dementia: a GENFI study.","date":"2017","source":"Brain : a journal of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/28460069","citation_count":52,"is_preprint":false},{"pmid":"30390709","id":"PMC_30390709","title":"Variation in TMEM106B in chronic traumatic encephalopathy.","date":"2018","source":"Acta neuropathologica communications","url":"https://pubmed.ncbi.nlm.nih.gov/30390709","citation_count":51,"is_preprint":false},{"pmid":"32761777","id":"PMC_32761777","title":"Loss of Tmem106b exacerbates FTLD pathologies and causes motor deficits in progranulin-deficient mice.","date":"2020","source":"EMBO reports","url":"https://pubmed.ncbi.nlm.nih.gov/32761777","citation_count":50,"is_preprint":false},{"pmid":"34526147","id":"PMC_34526147","title":"Analysis of genes (TMEM106B, GRN, ABCC9, KCNMB2, and APOE) implicated in risk for LATE-NC and hippocampal sclerosis provides pathogenetic insights: a retrospective genetic association study.","date":"2021","source":"Acta neuropathologica communications","url":"https://pubmed.ncbi.nlm.nih.gov/34526147","citation_count":48,"is_preprint":false},{"pmid":"32572497","id":"PMC_32572497","title":"A role of the frontotemporal lobar degeneration risk factor TMEM106B in myelination.","date":"2020","source":"Brain : a journal of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/32572497","citation_count":47,"is_preprint":false},{"pmid":"24872421","id":"PMC_24872421","title":"Regulated intramembrane proteolysis of the frontotemporal lobar degeneration risk factor, TMEM106B, by signal peptide peptidase-like 2a (SPPL2a).","date":"2014","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/24872421","citation_count":43,"is_preprint":false},{"pmid":"31709544","id":"PMC_31709544","title":"Long noncoding MAGI2-AS3 promotes colorectal cancer progression through regulating miR-3163/TMEM106B axis.","date":"2019","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/31709544","citation_count":42,"is_preprint":false},{"pmid":"28126008","id":"PMC_28126008","title":"Elevated TMEM106B levels exaggerate lipofuscin accumulation and lysosomal dysfunction in aged mice with progranulin deficiency.","date":"2017","source":"Acta neuropathologica communications","url":"https://pubmed.ncbi.nlm.nih.gov/28126008","citation_count":42,"is_preprint":false},{"pmid":"24684749","id":"PMC_24684749","title":"TMEM106B expression is reduced in Alzheimer's disease brains.","date":"2014","source":"Alzheimer's research & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/24684749","citation_count":40,"is_preprint":false},{"pmid":"25085782","id":"PMC_25085782","title":"Defining the association of TMEM106B variants among frontotemporal lobar degeneration patients with GRN mutations and C9orf72 repeat expansions.","date":"2014","source":"Neurobiology of aging","url":"https://pubmed.ncbi.nlm.nih.gov/25085782","citation_count":39,"is_preprint":false},{"pmid":"24343233","id":"PMC_24343233","title":"Effect of TMEM106B polymorphism on functional network connectivity in asymptomatic GRN mutation carriers.","date":"2014","source":"JAMA neurology","url":"https://pubmed.ncbi.nlm.nih.gov/24343233","citation_count":38,"is_preprint":false},{"pmid":"26651479","id":"PMC_26651479","title":"TMEM106B, a frontotemporal lobar dementia (FTLD) modifier, associates with FTD-3-linked CHMP2B, a complex of ESCRT-III.","date":"2015","source":"Molecular brain","url":"https://pubmed.ncbi.nlm.nih.gov/26651479","citation_count":35,"is_preprint":false},{"pmid":"30496365","id":"PMC_30496365","title":"Frontotemporal dementia causative CHMP2B impairs neuronal endolysosomal traffic-rescue by TMEM106B knockdown.","date":"2018","source":"Brain : a journal of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/30496365","citation_count":35,"is_preprint":false},{"pmid":"37726834","id":"PMC_37726834","title":"The major TMEM106B dementia risk allele affects TMEM106B protein levels, fibril formation, and myelin lipid homeostasis in the ageing human hippocampus.","date":"2023","source":"Molecular neurodegeneration","url":"https://pubmed.ncbi.nlm.nih.gov/37726834","citation_count":34,"is_preprint":false},{"pmid":"24252750","id":"PMC_24252750","title":"Expression of TMEM106B, the frontotemporal lobar degeneration-associated protein, in normal and diseased human brain.","date":"2013","source":"Acta neuropathologica communications","url":"https://pubmed.ncbi.nlm.nih.gov/24252750","citation_count":34,"is_preprint":false},{"pmid":"38232138","id":"PMC_38232138","title":"TMEM106B core deposition associates with TDP-43 pathology and is increased in risk SNP carriers for frontotemporal dementia.","date":"2024","source":"Science translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/38232138","citation_count":33,"is_preprint":false},{"pmid":"25851827","id":"PMC_25851827","title":"Identification of a novel TMEM106B-ROS1 fusion variant in lung adenocarcinoma by comprehensive genomic profiling.","date":"2015","source":"Lung cancer (Amsterdam, Netherlands)","url":"https://pubmed.ncbi.nlm.nih.gov/25851827","citation_count":33,"is_preprint":false},{"pmid":"37563705","id":"PMC_37563705","title":"TMEM106B aggregation in neurodegenerative diseases: linking genetics to function.","date":"2023","source":"Molecular neurodegeneration","url":"https://pubmed.ncbi.nlm.nih.gov/37563705","citation_count":32,"is_preprint":false},{"pmid":"28299358","id":"PMC_28299358","title":"A novel, potentially targetable TMEM106B-BRAF fusion in pleomorphic xanthoastrocytoma.","date":"2017","source":"Cold Spring Harbor molecular case studies","url":"https://pubmed.ncbi.nlm.nih.gov/28299358","citation_count":29,"is_preprint":false},{"pmid":"36056242","id":"PMC_36056242","title":"Identification of TMEM106B amyloid fibrils provides an updated view of TMEM106B biology in health and disease.","date":"2022","source":"Acta neuropathologica","url":"https://pubmed.ncbi.nlm.nih.gov/36056242","citation_count":28,"is_preprint":false},{"pmid":"29929528","id":"PMC_29929528","title":"Partial Tmem106b reduction does not correct abnormalities due to progranulin haploinsufficiency.","date":"2018","source":"Molecular neurodegeneration","url":"https://pubmed.ncbi.nlm.nih.gov/29929528","citation_count":28,"is_preprint":false},{"pmid":"28131462","id":"PMC_28131462","title":"Gene-based association study of genes linked to hippocampal sclerosis of aging neuropathology: GRN, TMEM106B, ABCC9, and KCNMB2.","date":"2017","source":"Neurobiology of aging","url":"https://pubmed.ncbi.nlm.nih.gov/28131462","citation_count":28,"is_preprint":false},{"pmid":"37100087","id":"PMC_37100087","title":"C-terminal TMEM106B fragments in human brain correlate with disease-associated TMEM106B haplotypes.","date":"2023","source":"Brain : a journal of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/37100087","citation_count":27,"is_preprint":false},{"pmid":"33991015","id":"PMC_33991015","title":"TMEM106B and CPOX are genetic determinants of cerebrospinal fluid Alzheimer's disease biomarker levels.","date":"2021","source":"Alzheimer's & dementia : the journal of the Alzheimer's Association","url":"https://pubmed.ncbi.nlm.nih.gov/33991015","citation_count":27,"is_preprint":false},{"pmid":"35287730","id":"PMC_35287730","title":"TMEM106B deficiency impairs cerebellar myelination and synaptic integrity with Purkinje cell loss.","date":"2022","source":"Acta neuropathologica communications","url":"https://pubmed.ncbi.nlm.nih.gov/35287730","citation_count":25,"is_preprint":false},{"pmid":"34152475","id":"PMC_34152475","title":"TMEM106B modifies TDP-43 pathology in human ALS brain and cell-based models of TDP-43 proteinopathy.","date":"2021","source":"Acta neuropathologica","url":"https://pubmed.ncbi.nlm.nih.gov/34152475","citation_count":24,"is_preprint":false},{"pmid":"33016371","id":"PMC_33016371","title":"Aged Tmem106b knockout mice display gait deficits in coincidence with Purkinje cell loss and only limited signs of non-motor dysfunction.","date":"2020","source":"Brain pathology (Zurich, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/33016371","citation_count":24,"is_preprint":false},{"pmid":"21614538","id":"PMC_21614538","title":"TMEM106B a novel risk factor for frontotemporal lobar degeneration.","date":"2011","source":"Journal of molecular neuroscience : MN","url":"https://pubmed.ncbi.nlm.nih.gov/21614538","citation_count":22,"is_preprint":false},{"pmid":"37146150","id":"PMC_37146150","title":"TMEM106B regulates microglial proliferation and survival in response to demyelination.","date":"2023","source":"Science advances","url":"https://pubmed.ncbi.nlm.nih.gov/37146150","citation_count":20,"is_preprint":false},{"pmid":"29855382","id":"PMC_29855382","title":"Loss of Tmem106b is unable to ameliorate frontotemporal dementia-like phenotypes in an AAV mouse model of C9ORF72-repeat induced toxicity.","date":"2018","source":"Acta neuropathologica communications","url":"https://pubmed.ncbi.nlm.nih.gov/29855382","citation_count":20,"is_preprint":false},{"pmid":"34347309","id":"PMC_34347309","title":"TMEM106B in humans and Vac7 and Tag1 in yeast are predicted to be lipid transfer proteins.","date":"2021","source":"Proteins","url":"https://pubmed.ncbi.nlm.nih.gov/34347309","citation_count":17,"is_preprint":false},{"pmid":"36012536","id":"PMC_36012536","title":"TMEM106B Acts as a Modifier of Cognitive and Motor Functions in Amyotrophic Lateral Sclerosis.","date":"2022","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/36012536","citation_count":16,"is_preprint":false},{"pmid":"39480813","id":"PMC_39480813","title":"TMEM106B-mediated SARS-CoV-2 infection allows for robust ACE2-independent infection in vitro but not in vivo.","date":"2024","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/39480813","citation_count":15,"is_preprint":false},{"pmid":"33314436","id":"PMC_33314436","title":"A novel temporal-predominant neuro-astroglial tauopathy associated with TMEM106B gene polymorphism in FTLD/ALS-TDP.","date":"2021","source":"Brain pathology (Zurich, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/33314436","citation_count":15,"is_preprint":false},{"pmid":"37077569","id":"PMC_37077569","title":"Case report: TMEM106B haplotype alters penetrance of GRN mutation in frontotemporal dementia family.","date":"2023","source":"Frontiers in neurology","url":"https://pubmed.ncbi.nlm.nih.gov/37077569","citation_count":15,"is_preprint":false},{"pmid":"38526616","id":"PMC_38526616","title":"TMEM106B coding variant is protective and deletion detrimental in a mouse model of tauopathy.","date":"2024","source":"Acta neuropathologica","url":"https://pubmed.ncbi.nlm.nih.gov/38526616","citation_count":14,"is_preprint":false},{"pmid":"38526799","id":"PMC_38526799","title":"Loss of TMEM106B exacerbates Tau pathology and neurodegeneration in PS19 mice.","date":"2024","source":"Acta neuropathologica","url":"https://pubmed.ncbi.nlm.nih.gov/38526799","citation_count":13,"is_preprint":false},{"pmid":"39237682","id":"PMC_39237682","title":"Lysosomal TMEM106B interacts with galactosylceramidase to regulate myelin lipid metabolism.","date":"2024","source":"Communications biology","url":"https://pubmed.ncbi.nlm.nih.gov/39237682","citation_count":12,"is_preprint":false},{"pmid":"33709463","id":"PMC_33709463","title":"Loss of Tmem106b leads to cerebellum Purkinje cell death and motor deficits.","date":"2021","source":"Brain pathology (Zurich, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/33709463","citation_count":12,"is_preprint":false},{"pmid":"39911968","id":"PMC_39911968","title":"A 3'UTR Insertion Is a Candidate Causal Variant at the TMEM106B Locus Associated With Increased Risk for FTLD-TDP.","date":"2024","source":"Neurology. Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/39911968","citation_count":12,"is_preprint":false},{"pmid":"36619668","id":"PMC_36619668","title":"Loss of TMEM106B exacerbates C9ALS/FTD DPR pathology by disrupting autophagosome maturation.","date":"2022","source":"Frontiers in cellular neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/36619668","citation_count":11,"is_preprint":false},{"pmid":"38886865","id":"PMC_38886865","title":"Cleaved TMEM106B forms amyloid aggregates in central and peripheral nervous systems.","date":"2024","source":"Acta neuropathologica communications","url":"https://pubmed.ncbi.nlm.nih.gov/38886865","citation_count":11,"is_preprint":false},{"pmid":"38924247","id":"PMC_38924247","title":"A common Alu insertion in the 3'UTR of TMEM106B is associated with risk of dementia.","date":"2024","source":"Alzheimer's & dementia : the journal of the Alzheimer's Association","url":"https://pubmed.ncbi.nlm.nih.gov/38924247","citation_count":11,"is_preprint":false},{"pmid":"33796852","id":"PMC_33796852","title":"Fronto-temporal dementia risk gene TMEM106B has opposing effects in different lysosomal storage disorders.","date":"2020","source":"Brain communications","url":"https://pubmed.ncbi.nlm.nih.gov/33796852","citation_count":11,"is_preprint":false},{"pmid":"36707901","id":"PMC_36707901","title":"Lack of a protective effect of the Tmem106b \"protective SNP\" in the Grn knockout mouse model for frontotemporal lobar degeneration.","date":"2023","source":"Acta neuropathologica communications","url":"https://pubmed.ncbi.nlm.nih.gov/36707901","citation_count":11,"is_preprint":false},{"pmid":"28477711","id":"PMC_28477711","title":"Association analysis of polymorphisms in VMAT2 and TMEM106B genes for Parkinson's disease, amyotrophic lateral sclerosis and multiple system atrophy.","date":"2017","source":"Journal of the neurological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/28477711","citation_count":11,"is_preprint":false},{"pmid":"32595021","id":"PMC_32595021","title":"A recurrent TMEM106B mutation in hypomyelinating leukodystrophy: A rapid diagnostic assay.","date":"2020","source":"Brain & development","url":"https://pubmed.ncbi.nlm.nih.gov/32595021","citation_count":10,"is_preprint":false},{"pmid":"37519899","id":"PMC_37519899","title":"AAV-GRN partially corrects motor deficits and ALS/FTLD-related pathology in Tmem106bGrn mice.","date":"2023","source":"iScience","url":"https://pubmed.ncbi.nlm.nih.gov/37519899","citation_count":9,"is_preprint":false},{"pmid":"40713630","id":"PMC_40713630","title":"The role of endolysosomal progranulin and TMEM106B in neurodegenerative diseases.","date":"2025","source":"Molecular neurodegeneration","url":"https://pubmed.ncbi.nlm.nih.gov/40713630","citation_count":7,"is_preprint":false},{"pmid":"40269985","id":"PMC_40269985","title":"Increased TMEM106B levels lead to lysosomal dysfunction which affects synaptic signaling and neuronal health.","date":"2025","source":"Molecular neurodegeneration","url":"https://pubmed.ncbi.nlm.nih.gov/40269985","citation_count":7,"is_preprint":false},{"pmid":"39709600","id":"PMC_39709600","title":"Physiological shedding and C-terminal proteolytic processing of TMEM106B.","date":"2024","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/39709600","citation_count":7,"is_preprint":false},{"pmid":"25096617","id":"PMC_25096617","title":"Association of TMEM106B rs1990622 marker and frontotemporal dementia: evidence for a recessive effect and meta-analysis.","date":"2015","source":"Journal of Alzheimer's disease : JAD","url":"https://pubmed.ncbi.nlm.nih.gov/25096617","citation_count":7,"is_preprint":false},{"pmid":"39711302","id":"PMC_39711302","title":"TMEM106B C-terminal fragments aggregate and drive neurodegenerative proteinopathy in transgenic Caenorhabditis elegans.","date":"2024","source":"Alzheimer's & dementia : the journal of the Alzheimer's Association","url":"https://pubmed.ncbi.nlm.nih.gov/39711302","citation_count":7,"is_preprint":false},{"pmid":"28888721","id":"PMC_28888721","title":"TMEM106B and ApoE polymorphisms in CHMP2B-mediated frontotemporal dementia (FTD-3).","date":"2017","source":"Neurobiology of aging","url":"https://pubmed.ncbi.nlm.nih.gov/28888721","citation_count":7,"is_preprint":false},{"pmid":"30332472","id":"PMC_30332472","title":"TMEM106B, a risk factor for FTLD and aging, has an intrinsically disordered cytoplasmic domain.","date":"2018","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/30332472","citation_count":7,"is_preprint":false},{"pmid":"39872397","id":"PMC_39872397","title":"Tracing TMEM106B fibril deposition in aging and Parkinson's disease with dementia brains.","date":"2024","source":"Life medicine","url":"https://pubmed.ncbi.nlm.nih.gov/39872397","citation_count":6,"is_preprint":false},{"pmid":"38710967","id":"PMC_38710967","title":"Physiological and pathological functions of TMEM106B in neurodegenerative diseases.","date":"2024","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/38710967","citation_count":6,"is_preprint":false},{"pmid":"32985120","id":"PMC_32985120","title":"Progranulin and TMEM106B: when two become wan.","date":"2020","source":"EMBO reports","url":"https://pubmed.ncbi.nlm.nih.gov/32985120","citation_count":6,"is_preprint":false},{"pmid":"39044012","id":"PMC_39044012","title":"TMEM106B Knockdown Exhibits a Neuroprotective Effect in Parkinson's Disease via Decreasing Inflammation and Iron Deposition.","date":"2024","source":"Molecular neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/39044012","citation_count":6,"is_preprint":false},{"pmid":"37545650","id":"PMC_37545650","title":"The identification of high-performing antibodies for transmembrane protein 106B (TMEM106B) for use in Western blot, immunoprecipitation, and immunofluorescence.","date":"2023","source":"F1000Research","url":"https://pubmed.ncbi.nlm.nih.gov/37545650","citation_count":6,"is_preprint":false},{"pmid":"37937069","id":"PMC_37937069","title":"Antibody-recognizing residues 188-211 of TMEM106B exhibit immunohistochemical reactivity with the TMEM106B C-terminal fragment.","date":"2023","source":"Frontiers in neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/37937069","citation_count":6,"is_preprint":false},{"pmid":"39321401","id":"PMC_39321401","title":"Gene-Specific Effects on Brain Volume and Cognition of TMEM106B in Frontotemporal Lobar Degeneration.","date":"2024","source":"Neurology","url":"https://pubmed.ncbi.nlm.nih.gov/39321401","citation_count":5,"is_preprint":false},{"pmid":"37965143","id":"PMC_37965143","title":"TMEM106B reduction does not rescue GRN deficiency in iPSC-derived human microglia and mouse models.","date":"2023","source":"iScience","url":"https://pubmed.ncbi.nlm.nih.gov/37965143","citation_count":5,"is_preprint":false},{"pmid":"37443768","id":"PMC_37443768","title":"TMEM106B Puncta Is Increased in Multiple Sclerosis Plaques, and Reduced Protein in Mice Results in Delayed Lipid Clearance Following CNS Injury.","date":"2023","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/37443768","citation_count":5,"is_preprint":false},{"pmid":"40011708","id":"PMC_40011708","title":"TMEM106B deficiency leads to alterations in lipid metabolism and obesity in the TDP-43Q331K knock-in mouse model.","date":"2025","source":"Communications biology","url":"https://pubmed.ncbi.nlm.nih.gov/40011708","citation_count":5,"is_preprint":false},{"pmid":"37541193","id":"PMC_37541193","title":"Unveiling TMEM106B: SARS-CoV-2's secret entrance to the cell.","date":"2023","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/37541193","citation_count":5,"is_preprint":false},{"pmid":"37461476","id":"PMC_37461476","title":"A 3'UTR Insertion Is a Candidate Causal Variant at the TMEM106B Locus Associated with Increased Risk for FTLD-TDP.","date":"2023","source":"medRxiv : the preprint server for health sciences","url":"https://pubmed.ncbi.nlm.nih.gov/37461476","citation_count":5,"is_preprint":false},{"pmid":"38206837","id":"PMC_38206837","title":"Novel Omicron Variants Enhance Anchored Recognition of TMEM106B: A New Pathway for SARS-CoV-2 Cellular Invasion.","date":"2024","source":"The journal of physical chemistry letters","url":"https://pubmed.ncbi.nlm.nih.gov/38206837","citation_count":5,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":53657,"output_tokens":8209,"usd":0.142053,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":17908,"output_tokens":6707,"usd":0.128608,"stage2_stop_reason":"end_turn"},"total_usd":0.270661,"stage1_batch_id":"msgbatch_0147LFpL5iCPFZF66xp23BqC","stage2_batch_id":"msgbatch_01Crtwc6eCsZh1CrnfJhY7J7","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2012,\n      \"finding\": \"TMEM106B is a type II integral membrane protein with a highly glycosylated luminal domain. Glycosylation (partially required for transport beyond the ER) was established by differential membrane extraction and sequential mutagenesis of N-glycosylation sites. Endogenous and overexpressed TMEM106B localizes to late endosomes and lysosomes. Inhibition of vacuolar H(+)-ATPase significantly increased TMEM106B protein levels.\",\n      \"method\": \"Differential membrane extraction, sequential N-glycosylation site mutagenesis, subcellular fractionation, immunofluorescence, vacuolar H(+)-ATPase inhibitor treatment\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — multiple orthogonal biochemical methods (mutagenesis, membrane extraction, pharmacological inhibition) in a single focused study establishing membrane topology and localization\",\n      \"pmids\": [\"22511793\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"TMEM106B overexpression induces enlargement and poor acidification of endo-lysosomes, impairs mannose-6-phosphate receptor trafficking, and increases intracellular progranulin levels. Endogenous neuronal TMEM106B co-localizes with progranulin in late endo-lysosomes. miR-132 and miR-212 repress TMEM106B expression through shared binding sites in its 3'UTR.\",\n      \"method\": \"TMEM106B overexpression in neurons, lysosomal pH assay, mannose-6-phosphate receptor trafficking assay, co-localization by immunofluorescence, microRNA binding site validation (luciferase reporter/empirical corroboration), microarray miRNA screen\",\n      \"journal\": \"The Journal of neuroscience : the official journal of the Society for Neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (overexpression phenotype, pH assay, trafficking assay, co-localization, miRNA reporter) converging on consistent findings\",\n      \"pmids\": [\"22895706\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"TMEM106B overexpression in cells localizes to late endosome/lysosome compartments, induces morphological changes in lysosomes, delays degradation of endocytic cargoes, and elevates intracellular progranulin levels, likely by attenuating lysosomal degradation of progranulin. TMEM106B protein levels are regulated by lysosomal activity.\",\n      \"method\": \"Ectopic TMEM106B expression, lysosomal inhibitor treatment, endocytic cargo degradation assay, progranulin level measurement by ELISA/western blot, immunofluorescence co-localization\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal assays (cargo degradation, progranulin quantification, localization) in a focused mechanistic study, consistent with independent findings in PMID:22895706\",\n      \"pmids\": [\"23136129\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"TMEM106B knockdown in primary neurons impairs lysosomal trafficking, blunts dendritic arborization, and increases retrograde lysosomal transport in dendrites. TMEM106B physically interacts with microtubule-associated protein 6 (MAP6). MAP6 overexpression phenocopies TMEM106B knockdown (reduced dendritic branching), and MAP6 knockdown fully rescues the dendritic phenotype of TMEM106B knockdown, consistent with a functional interaction. Expressing dominant-negative RILP to enhance anterograde lysosomal transport also rescues dendrite loss in TMEM106B knockdown neurons.\",\n      \"method\": \"shRNA knockdown in primary neurons, live-cell lysosome trafficking imaging, Co-immunoprecipitation (TMEM106B–MAP6), dendritic arborization morphometry, dominant-negative RILP expression, epistasis by double knockdown\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal functional epistasis, Co-IP for interaction, live imaging for trafficking, replicated across multiple genetic perturbations in one study\",\n      \"pmids\": [\"24357581\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"The TMEM106B coding variant T185S (rs3173615) affects protein stability: the T185 (risk) isoform is present at higher protein levels than S185 (protective) isoform. Cycloheximide chase experiments show S185 degrades faster than T185, potentially due to differences in N-glycosylation at residue N183. Both isoforms have similar effects on progranulin protein levels when overexpressed.\",\n      \"method\": \"Cycloheximide chase protein stability assay, TMEM106B-specific antibody characterization, ELISA for progranulin, overexpression of T185 and S185 variants\",\n      \"journal\": \"Journal of neurochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — cycloheximide chase directly establishes differential degradation rate; single lab, mechanistic follow-up with functional implication\",\n      \"pmids\": [\"23742080\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"TMEM106B undergoes regulated intramembrane proteolysis: it is processed by lysosomal proteases to generate an N-terminal fragment containing the transmembrane and intracellular domains, which is then further cleaved into a small, rapidly degraded intracellular domain by the GxGD aspartyl proteases SPPL2a and (to a lesser extent) SPPL2b. The TMEM106B paralog TMEM106A localizes to lysosomes but is not a substrate of SPPL2a or SPPL2b.\",\n      \"method\": \"Overexpression and inhibitor studies, SPPL2a/SPPL2b knockdown and overexpression, fragment detection by western blot, lysosomal protease inhibitor treatment\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — enzymatic mechanism established by protease identification with mutagenesis-equivalent gain/loss-of-function experiments; negative control (TMEM106A) strengthens specificity\",\n      \"pmids\": [\"24872421\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"TMEM106B associates with CHMP2B-positive structures (ESCRT-associated), suggesting involvement in ESCRT pathways. The T185 risk variant is more strongly localized to Rab7-positive late endosomes and more associated with CHMP2B compared to the S185 protective variant. T185 slightly reduces autophagic flux and enhances EGFR accumulation and neurotoxicity caused by mutant CHMP2B(Intron5) compared to S185.\",\n      \"method\": \"Co-immunoprecipitation (TMEM106B–CHMP2B), immunofluorescence co-localization with Rab5/Rab7, autophagic flux assay, EGFR accumulation assay, neurotoxicity assay\",\n      \"journal\": \"Molecular brain\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — Co-IP and co-localization establish interaction; autophagic flux and toxicity assays provide functional context; single lab\",\n      \"pmids\": [\"26651479\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Increased TMEM106B expression causes a lysosomal vacuolar phenotype in multiple cell types including neurons, impairs lysosomal acidification and degradative function, and increases cytotoxicity. A lysosomal sorting motif in TMEM106B is required for these effects; abrogation of lysosomal sorting rescues them. TMEM106B-induced lysosomal defects are dependent on C9orf72, as C9orf72 knockdown rescues these defects.\",\n      \"method\": \"TMEM106B overexpression in multiple cell lines and neurons, lysosomal pH assay, degradative function assay, cytotoxicity assay, lysosomal sorting motif mutagenesis, C9orf72 siRNA knockdown epistasis\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — lysosomal sorting motif mutagenesis (Tier 1 element), epistasis with C9orf72 knockdown, multiple cell types, multiple orthogonal readouts\",\n      \"pmids\": [\"27126638\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"TMEM106B binds vacuolar-ATPase accessory protein 1 (AP1). TMEM106B deficiency reduces vacuolar-ATPase AP1 and V0 subunits, impairing lysosomal acidification and normalizing elevated lysosomal enzyme levels seen in progranulin-null neurons. In Grn−/− mice, Tmem106b deletion normalizes lysosomal protein levels and rescues FTLD-related behavioral abnormalities and retinal degeneration.\",\n      \"method\": \"Co-immunoprecipitation (TMEM106B–vacuolar-ATPase AP1), lysosomal pH measurement, transcriptomic and proteomic analysis of Grn−/− and Tmem106b−/− mice, behavioral testing, retinal degeneration assessment\",\n      \"journal\": \"Neuron\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — Co-IP identifies binding partner; multiple orthogonal in vivo readouts; mechanistic link between TMEM106B, V-ATPase, and lysosomal acidification established across in vitro and in vivo experiments\",\n      \"pmids\": [\"28728022\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"TMEM106B knockdown rescues impaired endolysosomal trafficking and increased dendritic branching caused by mutant CHMP2B in neurons. Mechanistically, mutant CHMP2B stably incorporates onto neuronal endolysosomes and prevents their dendritic trafficking due to failure to recruit VPS4 ATPase (required for CHMP2B release). Antisense oligonucleotides (ASOs) targeting TMEM106B restore endosomal health in this context.\",\n      \"method\": \"ASO-mediated TMEM106B knockdown, live-cell endolysosome trafficking imaging in neurons, VPS4 recruitment assay, dendritic branching morphometry\",\n      \"journal\": \"Brain : a journal of neurology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — ASO knockdown with mechanistic pathway placement via VPS4/CHMP2B epistasis; live imaging with quantitative phenotype; multiple approaches in one study\",\n      \"pmids\": [\"30496365\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"TMEM106B drives lung cancer metastasis by promoting synthesis of enlarged lysosomes laden with elevated active cathepsins. In a TFEB-dependent manner, TMEM106B modulates lysosomal gene expression through the CLEAR pathway. TMEM106B-induced lysosomes undergo calcium-dependent exocytosis, releasing active cathepsins necessary for cancer cell invasion; pharmacological cathepsin inhibition prevents TMEM106B-mediated metastasis in vivo.\",\n      \"method\": \"Ectopic TMEM106B expression, in vivo metastasis assay (gain-of-function screen), lysosome size/number quantification, cathepsin activity assay, TFEB dependency (siRNA knockdown), calcium-dependent exocytosis assay, pharmacological cathepsin inhibition\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (in vivo screen, TFEB epistasis, cathepsin activity, exocytosis, pharmacological rescue) establishing the TFEB–lysosome–cathepsin secretion axis\",\n      \"pmids\": [\"30013069\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"The TMEM106B cytoplasmic domain (N-terminal, cytoplasmic-facing) is intrinsically disordered, with no well-defined tertiary structure, as demonstrated by CD and NMR spectroscopy. Several segments have dynamic/nascent secondary structures and relatively restricted backbone motions (ps-ns timescale), potentially allowing transient interactions with diverse partners.\",\n      \"method\": \"CD spectroscopy, multi-dimensional NMR spectroscopy ({1H}-15N steady-state NOE, chemical shift analysis)\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — direct structural characterization by NMR with CD corroboration; single lab but rigorous biophysical methods\",\n      \"pmids\": [\"30332472\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"TMEM106B deficiency in mice leads to enlarged LAMP1-positive vacuoles accumulating at the distal end and within the axon initial segment of motoneurons, increased retrograde axonal transport of lysosomes, lipofuscin accumulation, and autophagosome accumulation, resulting in impaired motor performance. TMEM106B mediates anterograde axonal transport of LAMP1-positive organelles and axonal sorting at the initial segment.\",\n      \"method\": \"TMEM106B-deficient mouse model, LAMP1 immunofluorescence/confocal imaging, live-cell axonal transport quantification, lipofuscin staining, autophagosome staining, motor behavior testing (facial-nerve-dependent assay)\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — knockout mouse model with multiple orthogonal readouts (transport imaging, vesicle morphology, behavioral testing) establishing lysosomal transport function at the axon initial segment\",\n      \"pmids\": [\"32160553\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"TMEM106B deficiency in mice causes myelination defects with significant reduction of proteolipid protein (PLP) and myelin oligodendrocyte glycoprotein (MOG) levels. TMEM106B localizes to lysosomes in oligodendrocytes, physically interacts with lysosomal protease cathepsin D, and is required to maintain proper cathepsin D levels. TMEM106B deficiency causes lysosome clustering in the perinuclear region and decreased lysosome exocytosis and cell-surface PLP levels. The disease-linked D252N mutation abolishes lysosome enlargement and acidification induced by wild-type TMEM106B overexpression, and instead promotes lysosome perinuclear clustering similar to TMEM106B deficiency.\",\n      \"method\": \"TMEM106B-deficient mice and Oli-neu cell line, immunofluorescence, western blot (PLP, MOG, cathepsin D), Co-immunoprecipitation (TMEM106B–cathepsin D), lysosome exocytosis assay, cell-surface PLP measurement, D252N mutant overexpression, lysosomal pH assay\",\n      \"journal\": \"Brain : a journal of neurology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — Co-IP establishes binding partner; multiple orthogonal methods in both cell and mouse models; mutant analysis (D252N) provides mechanistic discrimination\",\n      \"pmids\": [\"32572497\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"TMEM106B is required for SARS-CoV-2 infection of human cell lines and primary lung cells. TMEM106B overexpression enhances SARS-CoV-2 infection and pseudovirus infection, implicating a role in viral entry. Identified by genome-wide CRISPR functional screen.\",\n      \"method\": \"Genome-wide CRISPR knockout screen, SARS-CoV-2 infection assay (cell lines and primary lung cells), TMEM106B overexpression/pseudovirus infection assay\",\n      \"journal\": \"Nature genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genome-wide unbiased screen validated by overexpression gain-of-function; multiple cell types tested; consistent with independently published finding\",\n      \"pmids\": [\"33686287\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"TMEM106B is predicted, by sequence analysis using PSI-BLAST, HMMER, HHpred, and trRosetta, to contain a late embryogenesis abundant-2 (LEA-2) domain superfamily fold in its luminal domain, which has a conserved lipid-binding groove, suggesting TMEM106B may function as a lipid transfer protein in the lumen of late endocytic organelles.\",\n      \"method\": \"Computational sequence analysis (PSI-BLAST, HMMER, HHpred, trRosetta structure prediction)\",\n      \"journal\": \"Proteins\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 4 / Weak — computational prediction only; no experimental validation of lipid transfer activity in this paper\",\n      \"pmids\": [\"34347309\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Residues 120–254 of the C-terminal luminal domain of TMEM106B form amyloid filaments in human brains with diverse neurodegenerative diseases (tauopathies, amyloid-β amyloidoses, synucleinopathies, TDP-43 proteinopathies) and in neurologically normal aged individuals. Three distinct TMEM106B fibril folds were identified, with no clear relationship between fold and disease type. TMEM106B filaments correlate with a 29-kDa sarkosyl-insoluble fragment and globular cytoplasmic inclusions and form in an age-dependent manner.\",\n      \"method\": \"Cryo-electron microscopy structure determination, sarkosyl fractionation, C-terminal-specific antibody immunodetection, postmortem human brain analysis\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — cryo-EM structure determination at atomic/near-atomic resolution across 22 subjects and multiple disease types; independently replicated by parallel publication (PMID:35344984, PMID:35247328)\",\n      \"pmids\": [\"35344985\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Amyloid fibrils extracted from FTLD-TDP brains (four FTLD-TDP subclasses) are composed of a 135-residue C-terminal fragment of TMEM106B (not TDP-43 as previously assumed). TDP-43 is present as non-fibrillar aggregates detected by immunogold labelling. TMEM106B fibril structure was solved by cryo-EM.\",\n      \"method\": \"Cryo-EM structure determination of amyloid fibrils from postmortem FTLD-TDP brain, immunogold labelling for TDP-43, biochemical extraction of fibrils\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — atomic-resolution cryo-EM structure with immunogold verification; consistent with independent parallel publications\",\n      \"pmids\": [\"35344984\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"A 135-amino acid C-terminal fragment of TMEM106B forms amyloid fibrils (structure solved at 2.7 Å resolution) common to FTLD-TDP, progressive supranuclear palsy, and dementia with Lewy bodies. The fibril structure is homotypic and consistent across distinct neurodegenerative diseases.\",\n      \"method\": \"Cryo-electron microscopy (2.7 Å resolution), mass spectrometry, postmortem human brain tissue from multiple diseases\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — near-atomic cryo-EM structure with MS validation across multiple disease types; independent replication of PMID:35344985 and PMID:35344984\",\n      \"pmids\": [\"35247328\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"TMEM106B loss causes a block late in autophagy by disrupting autophagosome-to-autolysosome maturation, coinciding with impaired lysosomal acidification, reduced cathepsin activity, and juxtanuclear lysosome clustering. Lysosomal clustering requires Rab7A and is associated with reduced Arl8b-mediated anterograde lysosomal transport. Restoring Arl8b activity in TMEM106B-deficient cells rescues lysosome distribution, autophagy, and DPR protein accumulation.\",\n      \"method\": \"TMEM106B siRNA knockdown, autophagosome–autolysosome maturation assay (tandem fluorescent LC3 reporter), lysosomal pH measurement, cathepsin activity assay, live-cell lysosome distribution imaging, Rab7A siRNA epistasis, Arl8b overexpression rescue\",\n      \"journal\": \"Frontiers in cellular neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal autophagy/lysosomal assays; genetic epistasis (Rab7A, Arl8b) with rescue; identifies specific mechanistic step (autophagosome maturation via Arl8b)\",\n      \"pmids\": [\"36619668\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"TMEM106B serves as an ACE2-independent receptor for SARS-CoV-2 entry into ACE2-negative cells. The luminal domain (LD) of TMEM106B directly engages the receptor-binding motif of SARS-CoV-2 spike (established by X-ray crystallography, cryo-EM, and HDX-MS). Spike substitution E484D enhances TMEM106B binding and TMEM106B-mediated entry. TMEM106B-specific monoclonal antibodies block SARS-CoV-2 infection. TMEM106B also promotes spike-mediated syncytium formation, suggesting a role in viral membrane fusion. TMEM106B acts cooperatively with heparan sulfate.\",\n      \"method\": \"X-ray crystallography, cryo-EM, hydrogen-deuterium exchange mass spectrometry (HDX-MS), pseudovirus entry assay, monoclonal antibody blocking, syncytium formation assay, ACE2-negative cell infection assay\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — atomic-resolution structure of TMEM106B–spike complex by multiple orthogonal structural methods (X-ray, cryo-EM, HDX-MS) plus functional antibody blocking and entry assays in one rigorous study\",\n      \"pmids\": [\"37421949\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"TMEM106B deficiency in mice reduces microglial proliferation and activation and increases microglial apoptosis in response to demyelination. TMEM106B-deficient microglia have increased lysosomal pH and decreased lysosomal enzyme activities. TMEM106B loss causes significant decrease in TREM2 protein levels in microglia. Microglial-specific TMEM106B ablation recapitulates these phenotypes and causes myelination defects.\",\n      \"method\": \"Conditional (microglial-specific) TMEM106B knockout mice, demyelination model, microglial proliferation/apoptosis assays, lysosomal pH measurement, lysosomal enzyme activity assay, TREM2 western blot, myelination assessment\",\n      \"journal\": \"Science advances\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — cell-type-specific conditional knockout with multiple orthogonal mechanistic readouts (TREM2 levels, lysosomal pH, enzyme activity, proliferation) in a focused mechanistic study\",\n      \"pmids\": [\"37146150\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"The luminal domain of TMEM106B is cleaved by multiple lysosomal cysteine-type proteases to generate the C-terminal fragment capable of fibril formation. Cysteine-type proteases also perform additional C-terminal trimming of this fragment. Fibrillar TMEM106B was detected in human autopsy material. These cleavage events occur under physiological conditions in cellular models and mouse models.\",\n      \"method\": \"Cysteine protease inhibitors, custom antibody against luminal domain, western blot in knockout and wild-type cellular/mouse models, immunodetection of fibrils in human autopsy material\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — protease identity established by pharmacological inhibition in well-controlled KO vs. WT models; fibril detection in human tissue; commercially available antibody validated in KO controls\",\n      \"pmids\": [\"39709600\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"TMEM106B physically interacts with galactosylceramidase (co-immunoprecipitation). TMEM106B deficiency significantly increases galactosylceramidase activity and decreases levels of galactosylceramide and sulfatide (major myelin lipids) in mouse brain, establishing that TMEM106B regulates myelin lipid metabolism through modulation of galactosylceramidase.\",\n      \"method\": \"Lipidomic analysis of TMEM106B-deficient mouse brain, co-immunoprecipitation (TMEM106B–galactosylceramidase), galactosylceramidase activity assay\",\n      \"journal\": \"Communications biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — Co-IP establishes physical interaction; lipidomics and enzyme activity assay provide orthogonal functional evidence; in vivo mouse model\",\n      \"pmids\": [\"39237682\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"TMEM106B deletion in a tauopathy mouse model (P301S tau) accelerates cognitive decline, hind limb paralysis, tau pathology, and neurodegeneration. In contrast, the T185S (T186S in mouse) coding variant protects against tau-associated cognitive decline, synaptic impairment, neurodegeneration, and paralysis without affecting tau pathology itself, demonstrating the coding variant is functionally relevant and acts downstream of tau aggregation.\",\n      \"method\": \"TMEM106B knockout and T186S knock-in mice crossed with P301S tau transgenic model, behavioral testing (cognitive, motor), tau pathology quantification, synaptic marker analysis, neurodegeneration assessment, transcriptomic correlation with human AD\",\n      \"journal\": \"Acta neuropathologica\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — parallel KO and knock-in alleles in tauopathy model; multiple orthogonal phenotypic readouts; genetic dissection of variant-specific effects in a single study\",\n      \"pmids\": [\"38526616\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Loss of TMEM106B enhances accumulation of pathological tau (especially in neuronal soma in hippocampus) and causes severe neuronal loss, cytoskeletal abnormalities, increased autophagy-lysosome dysfunction, and glial activation in PS19 tau transgenic mice, indicating TMEM106B is required to limit tau pathology progression.\",\n      \"method\": \"Tmem106b−/− × PS19 tau transgenic cross, immunofluorescence for phospho-tau, neuronal count, cytoskeletal markers, autophagy-lysosome markers, glial activation markers\",\n      \"journal\": \"Acta neuropathologica\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — double transgenic mouse model with multiple orthogonal readouts; independently replicates finding of PMID:38526616 in a distinct tau model\",\n      \"pmids\": [\"38526799\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Partial knockdown of TMEM106B (to levels expected in rs1990622 C-allele carriers) in an inducible TDP-43 mislocalization cell system leads to more TDP-43 cytoplasmic aggregates that are more insoluble, supporting a causal role for TMEM106B in modifying TDP-43 proteinopathy.\",\n      \"method\": \"Inducible TDP-43 mislocalization cell system, TMEM106B siRNA partial knockdown, TDP-43 aggregate quantification, solubility fractionation (filter trap assay)\",\n      \"journal\": \"Acta neuropathologica\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — clean cell-based mechanistic experiment with defined phenotype; single lab, single experimental system\",\n      \"pmids\": [\"34152475\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Transgenic mice overexpressing human TMEM106B (4–8-fold increase) develop lysosomal dysfunction, age-related downregulation of genes associated with neuronal plasticity and memory, altered synaptic signaling, anxiety-like phenotype, and mild hippocampal neuronal loss, establishing that elevated TMEM106B levels are sufficient to impair lysosomal and neuronal health.\",\n      \"method\": \"Cre-inducible transgenic mouse model, transmission electron microscopy, immunostaining, behavioral testing, electrophysiology, bulk RNA sequencing\",\n      \"journal\": \"Molecular neurodegeneration\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — first transgenic overexpression mouse model; multiple orthogonal readouts (EM, electrophysiology, behavior, transcriptomics); establishes gain-of-function lysosomal and neuronal consequences\",\n      \"pmids\": [\"40269985\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"TMEM106B is a type II integral membrane protein resident in late endosomes and lysosomes, where it regulates lysosomal morphology, acidification (through interaction with vacuolar-ATPase subunits), lysosomal enzyme levels, anterograde axonal and dendritic lysosomal transport (via interaction with MAP6), and autophagosome-to-autolysosome maturation (via Arl8b); its luminal domain is cleaved by lysosomal cysteine proteases, and the resulting C-terminal fragment (residues 120–254) forms age-dependent amyloid fibrils with three distinct cryo-EM-resolved folds found across diverse neurodegenerative diseases; TMEM106B also interacts with galactosylceramidase to regulate myelin lipid metabolism, promotes microglial lysosomal function and TREM2 levels, and acts as an ACE2-independent entry receptor for SARS-CoV-2 through direct spike RBM engagement of its luminal domain.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"TMEM106B is a type II integral membrane protein resident in late endosomes and lysosomes that governs lysosomal morphology, acidification, positioning, and degradative capacity, thereby acting as a central regulator of endolysosomal and autophagic homeostasis in neurons, glia, and other cell types [#0, #1, #7]. Its highly glycosylated luminal domain faces the lysosomal lumen, while its intrinsically disordered cytoplasmic N-terminus enables transient interactions; protein levels are tuned by lysosomal activity and by the miR-132/miR-212 cluster [#0, #11, #1]. TMEM106B promotes lysosomal acidification by binding the vacuolar-ATPase accessory protein AP1 and supporting V-ATPase subunit levels, and its loss reduces acidification and normalizes the elevated lysosomal enzyme and protein levels seen in progranulin-null neurons—Tmem106b deletion rescues FTLD-related phenotypes in Grn-/- mice [#8]. It controls anterograde lysosomal transport along axons and dendrites through interaction with MAP6 and through Arl8b-dependent positioning, such that its loss causes retrograde transport bias, perinuclear/juxtanuclear lysosome clustering, and a block in autophagosome-to-autolysosome maturation [#3, #12, #19]. TMEM106B regulates lysosomal protease and lipid metabolism via physical interactions with cathepsin D and galactosylceramidase, controlling myelin lipid (galactosylceramide/sulfatide) levels and oligodendrocyte function, and it sustains microglial lysosomal function and TREM2 levels [#13, #23, #21]. The luminal domain is cleaved by lysosomal cysteine proteases to generate a C-terminal fragment (residues ~120–254) that forms age-dependent amyloid fibrils with three distinct cryo-EM folds across diverse neurodegenerative diseases—these fibrils, rather than TDP-43, constitute the filaments previously attributed to FTLD-TDP brains [#22, #16, #17, #18]. Both gain and loss of TMEM106B are pathogenic: overexpression causes lysosomal vacuolation, impaired acidification, cytotoxicity, and neuronal dysfunction, while loss accelerates tau and TDP-43 proteinopathy, and the protective T185S coding variant acts downstream of tau aggregation to preserve neuronal health [#7, #27, #24, #26]. Independently of its lysosomal role, TMEM106B serves as an ACE2-independent entry receptor for SARS-CoV-2, with its luminal domain directly engaging the spike receptor-binding motif [#20, #14].\",\n  \"teleology\": [\n    {\n      \"year\": 2012,\n      \"claim\": \"Establishing that TMEM106B is a glycosylated type II membrane protein resident in late endosomes/lysosomes whose levels are set by lysosomal activity defined the compartment in which all subsequent function would be interpreted.\",\n      \"evidence\": \"Differential membrane extraction, N-glycosylation mutagenesis, fractionation, and V-ATPase inhibitor treatment\",\n      \"pmids\": [\"22511793\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Topology established but luminal-domain function not defined\", \"No partners identified at this stage\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Demonstrating that TMEM106B overexpression enlarges and de-acidifies lysosomes, impairs M6PR trafficking and cargo degradation, and raises progranulin levels linked the protein mechanistically to lysosomal degradative function and the FTLD progranulin axis.\",\n      \"evidence\": \"Overexpression in neurons/cells, lysosomal pH and trafficking assays, progranulin ELISA, miRNA reporter validation\",\n      \"pmids\": [\"22895706\", \"23136129\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Gain-of-function phenotype; physiological loss-of-function role unresolved\", \"Direct molecular cause of acidification defect not identified\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Identifying the MAP6 interaction and reciprocal epistasis established that TMEM106B drives anterograde lysosomal transport required for dendritic arborization, moving the protein from a static lysosomal marker to a transport regulator.\",\n      \"evidence\": \"shRNA knockdown in primary neurons, live lysosome imaging, Co-IP, dominant-negative RILP rescue, double knockdown\",\n      \"pmids\": [\"24357581\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct biochemical bridge between luminal TMEM106B and cytoplasmic motor machinery not resolved\", \"Whether MAP6 binding is direct vs. complex-mediated unclear\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Showing that the risk T185 isoform is more stable than the protective S185 isoform provided a candidate molecular basis for the disease-associated coding variant.\",\n      \"evidence\": \"Cycloheximide chase stability assay, isoform-specific overexpression, progranulin ELISA\",\n      \"pmids\": [\"23742080\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Stability difference correlated with but not proven to cause disease risk\", \"Glycosylation mechanism at N183 inferred, not directly demonstrated\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Defining regulated intramembrane proteolysis by lysosomal proteases and SPPL2a/SPPL2b established a processing pathway for TMEM106B and distinguished it from the non-substrate paralog TMEM106A.\",\n      \"evidence\": \"SPPL2a/SPPL2b knockdown/overexpression, protease inhibitors, fragment western blots\",\n      \"pmids\": [\"24872421\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional consequence of the released intracellular fragment unknown\", \"Relationship of this processing to fibril-forming luminal fragment not yet connected\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Mapping the lysosomal sorting motif requirement and C9orf72 dependence of the overexpression phenotype tied TMEM106B-driven lysosomal toxicity to specific trafficking determinants and a known FTD/ALS gene.\",\n      \"evidence\": \"Overexpression in multiple cell types, sorting motif mutagenesis, lysosomal pH/degradation/cytotoxicity assays, C9orf72 siRNA epistasis\",\n      \"pmids\": [\"27126638\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular nature of C9orf72 dependence not defined\", \"ESCRT/CHMP2B association reported separately but mechanistically incomplete\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Identifying the V-ATPase accessory protein AP1 as a binding partner and showing Tmem106b deletion rescues Grn-/- lysosomal and behavioral phenotypes established the molecular basis of TMEM106B-dependent acidification and its in vivo modifier role in FTLD.\",\n      \"evidence\": \"Co-IP, lysosomal pH measurement, transcriptomics/proteomics in Grn-/- × Tmem106b-/- mice, behavioral and retinal assessment\",\n      \"pmids\": [\"28728022\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct stoichiometry/assembly with V-ATPase not resolved\", \"Whether AP1 binding is luminal or cytoplasmic not specified\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"A series of studies extended TMEM106B function to autophagic flux (CHMP2B/ESCRT context), VPS4-dependent endolysosome trafficking, cancer metastasis via TFEB-driven lysosomal cathepsin secretion, and defined its cytoplasmic domain as intrinsically disordered, broadening its mechanistic reach.\",\n      \"evidence\": \"Co-IP, CHMP2B/VPS4 epistasis, in vivo metastasis and cathepsin/exocytosis assays with TFEB knockdown, CD/NMR spectroscopy\",\n      \"pmids\": [\"26651479\", \"30496365\", \"30013069\", \"30332472\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How disordered cytoplasmic domain selects diverse partners undefined\", \"Direct vs. indirect role in TFEB/CLEAR regulation unresolved\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Knockout mice revealed that TMEM106B mediates anterograde axonal lysosome transport and axon-initial-segment sorting and physically interacts with cathepsin D to regulate myelination, linking lysosomal positioning and protease control to neuronal and oligodendrocyte integrity.\",\n      \"evidence\": \"TMEM106B-deficient mice and Oli-neu cells, axonal transport imaging, lipofuscin/autophagosome staining, motor testing, Co-IP with cathepsin D, D252N mutant analysis\",\n      \"pmids\": [\"32160553\", \"32572497\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism by which D252N inverts the gain-of-function phenotype not fully resolved\", \"Direct vs. regulatory role on cathepsin D activity unclear\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"A genome-wide CRISPR screen identified TMEM106B as required for SARS-CoV-2 infection and entry, revealing a function entirely distinct from its lysosomal role.\",\n      \"evidence\": \"Genome-wide CRISPR knockout screen, infection of cell lines/primary lung cells, overexpression/pseudovirus assays\",\n      \"pmids\": [\"33686287\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism of entry (receptor vs. cofactor) not yet defined in this study\", \"Relationship to lysosomal residence unclear\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Computational analysis predicting a LEA-2 lipid-binding fold in the luminal domain offered a structural hypothesis for a lipid-handling function.\",\n      \"evidence\": \"PSI-BLAST, HMMER, HHpred, trRosetta structure prediction\",\n      \"pmids\": [\"34347309\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"Computational prediction only; no experimental validation of lipid transfer activity\", \"Predicted fold not yet reconciled with experimental luminal structures\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Partial knockdown mimicking risk-allele expression increased and insolubilized TDP-43 cytoplasmic aggregates, providing causal support for TMEM106B as a modifier of TDP-43 proteinopathy.\",\n      \"evidence\": \"Inducible TDP-43 mislocalization cell system, siRNA partial knockdown, aggregate quantification, filter-trap solubility assay\",\n      \"pmids\": [\"34152475\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single cell-based system; in vivo confirmation absent here\", \"Mechanism connecting lysosomal function to TDP-43 aggregation not defined\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Cryo-EM determination of TMEM106B amyloid fibrils from human brain established that the C-terminal luminal fragment, not TDP-43, forms the filaments in FTLD-TDP and across diverse neurodegenerative diseases and aged brains, overturning a prior assumption and defining an age-dependent amyloid.\",\n      \"evidence\": \"Cryo-EM structure determination across multiple diseases/subjects, sarkosyl fractionation, immunogold for TDP-43, mass spectrometry\",\n      \"pmids\": [\"35344985\", \"35344984\", \"35247328\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether fibrils are pathogenic, protective, or bystander not resolved\", \"No clear fold–disease relationship established\", \"Trigger of age-dependent fibril formation unknown\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Demonstrating an Arl8b- and Rab7A-dependent block in autophagosome-to-autolysosome maturation upon TMEM106B loss placed the protein at a defined step of autophagy and lysosomal positioning, with Arl8b restoration rescuing the defect.\",\n      \"evidence\": \"siRNA knockdown, tandem LC3 maturation reporter, lysosomal pH and cathepsin assays, Rab7A epistasis, Arl8b overexpression rescue\",\n      \"pmids\": [\"36619668\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct interaction with Arl8b vs. indirect regulation not established\", \"Link between maturation block and DPR accumulation mechanism incomplete\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Structural determination of the TMEM106B luminal domain–spike complex established TMEM106B as a bona fide ACE2-independent SARS-CoV-2 entry receptor engaging the spike receptor-binding motif, with neutralizing antibody and syncytium evidence.\",\n      \"evidence\": \"X-ray crystallography, cryo-EM, HDX-MS, pseudovirus entry, monoclonal antibody blocking, syncytium assay\",\n      \"pmids\": [\"37421949\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo relevance to COVID-19 pathology not established here\", \"Interplay with ACE2-positive cells unclear\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Microglial-specific knockout showed TMEM106B sustains microglial lysosomal function and TREM2 levels and supports proliferation/survival during demyelination, extending its role into neuroimmune lysosomal biology.\",\n      \"evidence\": \"Conditional microglial knockout mice, demyelination model, proliferation/apoptosis assays, lysosomal pH and enzyme activity, TREM2 western blot\",\n      \"pmids\": [\"37146150\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism linking TMEM106B to TREM2 stability not defined\", \"Direct vs. lysosome-mediated effect on TREM2 unclear\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Identifying lysosomal cysteine proteases as the enzymes that cleave and trim the luminal domain to the fibril-forming fragment connected physiological proteolysis to amyloid generation.\",\n      \"evidence\": \"Cysteine protease inhibitors, luminal-domain antibody, western blots in KO vs WT cells/mice, fibril detection in human autopsy tissue\",\n      \"pmids\": [\"39709600\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Specific protease identity at species level not narrowed\", \"Why cleavage products become amyloidogenic with age unresolved\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"The galactosylceramidase interaction and lipidomic consequences of TMEM106B loss established that TMEM106B regulates myelin lipid metabolism by modulating a lysosomal lipid-degrading enzyme.\",\n      \"evidence\": \"Co-IP, galactosylceramidase activity assay, brain lipidomics in TMEM106B-deficient mice\",\n      \"pmids\": [\"39237682\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether TMEM106B inhibits or scaffolds galactosylceramidase mechanistically unclear\", \"Connection to predicted luminal lipid-binding fold not tested\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Crossing TMEM106B knockout and T185S knock-in alleles into tauopathy models demonstrated that loss accelerates tau pathology and neurodegeneration while the protective coding variant preserves neuronal health downstream of tau aggregation, proving the variant is functionally relevant in vivo.\",\n      \"evidence\": \"Tmem106b KO and T186S knock-in × P301S/PS19 tau mice, behavioral/motor testing, tau pathology and synaptic/neurodegeneration readouts\",\n      \"pmids\": [\"38526616\", \"38526799\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular pathway by which TMEM106B limits tau-driven degeneration not fully defined\", \"How T185S acts downstream of tau aggregation mechanistically unclear\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"A transgenic overexpression mouse model established that elevated TMEM106B levels alone are sufficient to cause lysosomal dysfunction, synaptic/transcriptomic decline, and neuronal loss, confirming pathogenic gain of function in vivo.\",\n      \"evidence\": \"Cre-inducible transgenic mice, electron microscopy, electrophysiology, behavior, bulk RNA-seq\",\n      \"pmids\": [\"40269985\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether overexpression toxicity proceeds via fibril formation untested here\", \"Relationship of gain-of-function to loss-of-function phenotypes unresolved\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Whether the age-dependent amyloid fibrils are pathogenic, protective, or incidental, and how a single protein reconciles opposing gain- and loss-of-function disease mechanisms, remains the central unresolved question.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No causal demonstration that fibrils drive neurodegeneration\", \"No unified model linking lysosomal dysfunction, fibril formation, and the protective coding variant\", \"Physiological function of the predicted luminal lipid-binding fold experimentally untested\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [3, 8, 23, 13]},\n      {\"term_id\": \"GO:0001618\", \"supporting_discovery_ids\": [20, 14]},\n      {\"term_id\": \"GO:0005198\", \"supporting_discovery_ids\": [16, 17, 18]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005764\", \"supporting_discovery_ids\": [0, 1, 2, 7, 13]},\n      {\"term_id\": \"GO:0005768\", \"supporting_discovery_ids\": [0, 6, 9]},\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [20]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-9612973\", \"supporting_discovery_ids\": [19, 6]},\n      {\"term_id\": \"R-HSA-5653656\", \"supporting_discovery_ids\": [3, 12, 19]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [16, 17, 24, 25, 26]},\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [23, 13]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"MAP6\", \"ATP6AP1\", \"CHMP2B\", \"CTSD\", \"GALC\", \"ARL8B\", \"RAB7A\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win"}}